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Retinopathy of Prematurity (ROP) is an important cause of partial sight or blindness 
in prematurely born infants. Worldwide assessment in 2010 estimated that 21.8% of 
preterm born infants born has some degree of ROP.1 Incidence figures for ROP and visual 
disability due to ROP differ however per country, region or continent. Worldwide ROP 
accounts for 17.5% of visual impairment in prematurely born babies.
In middle income countries like many Latin American and Asian countries and the For-
mer Socialist Countries of Eastern Europe, ROP is emerging as a major cause of blindness 
(also referred to as the “third epidemic”).2 Possible reasons for this epidemic are:
•	 birth	rates	and	rates	of	premature	birth	are	increasing;
•	 neonatal	care	may	be	compromised	as	a	result	of	limitation	of	resources,	resulting	in	
higher rates of severe ROP not only in extremely premature infants but also in bigger, 
more	mature	infants;	and
•	 no	nationwide	implementation	of	screening	and	treatment	programs	due	to	the	lack	
of awareness, skilled personnel and/or financial resources.3
For example, a third of all children under the age of ten in schools for the visually 
impaired in Vietnam and more than 40% of under-5 years of age in similar schools in 
Mexico are blind as a result of ROP.4 In lower income countries the incidence of ROP is 
low as neonatal care is not well developed, so less premature infants survive.5
Permanent visual damage will increase with increasing prematurity of the infant. Over 
the past two decades changes in neonatal care have increased the survival rate of very 
small and very preterm infants, also in the Netherlands. Significant progress in health 
care practice like the introduction of surfactant, increased use of antenatal steroids, 
resuscitation of infants with lower gestational ages, improved nutrition and prophylac-
tic use of indomethacin have contributed to this increased survival. Consequently an 
increasing number of infants is at risk, not only for visual impairment (VI) caused by ROP 
or cerebral visual impairment (CVI), but also for non-visual disabilities.6-10 Termote et al 
found a significant increase in behavioral abnormalities in infants with visual impair-
ment due to ROP, born between 1994 and 2000.11
The last national survey in the Netherlands showed that 8-10 infants per year become 
visually disabled or blind as a consequence of ROP.11 Visual impairment due to ROP can 
be decreased by timely screening, thorough follow up and prompt treatment of neo-
nates who are at risk. So a dedicated screening program is indispensable. However, as 
reported, incidences of ROP strongly depend on study cohort, level of care and country, 
so screening guidelines cannot be applied uniformly in different countries. For that 
reason it is important to define and to inventorize the population at risk for potentially 
blinding ROP and to provide evidence for a quality guideline per country.
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HISTORY
ROP was first reported in 1942 by Terry, who described the histological findings of what 
would now be considered end-stage, cicatricial disease but back then was called retro-
lental fibroplasia (RLF).12
The first ROP epidemic, occurring in the USA from the 1940s until late 50s, was caused 
by	administering	high	doses	of	oxygen	to	premature	infants	without	monitoring;	pulse	
oximetry was not yet available.13-19 As a reaction to this, attempts were made to curtail 
oxygen use in the premature nursery by administering oxygen only at times of clinical 
need, as short a period as possible and at concentrations less than 40%.20 Although rates 
of ROP decreased, cerebral palsy and death increased, blocking the implementation of 
a restricted oxygen regimen.17;18
With the introduction of pulse oximetry in the 1970s, oxygen administration became 
more controlled and it was anticipated that ROP would disappear. Research by Patz14 
and by Kinsey et al16, and laboratory experiments by Ashton21, suggested that ROP could 
be entirely preventable by thorough oxygen regulation. Unfortunately, this proved not 
to be the case.
In the 1970’s ROP incidence once again increased, referred to as the second epidemic, 
now as a consequence of increased survival rates of extremely premature babies.22 In 
those days ROP screening was performed by neonatologists who performed external 
examination of the eyes as well as direct ophthalmoscopy. However, by the time 
pathological retinal changes were evident to the neonatologist the disease was usually 
very advanced. This called for examination by experienced ophthalmologists. In 1976 
the AAP (American Academy of Pediatrics) issued the first screening guideline and 
recommended that screening examinations for ROP should be performed at the time 
of discharge from the nursery and at three to six month of age.23 The median length 
of stay in the neonatal intensive care unit (NICU) at that time was 61 days (almost 9 
weeks) for those with a birth weight (BW) of 751-1000gr, and 30 days for those with BW 
1000-1250gr. If there were no fundus abnormalities on discharge from the hospital, no 
follow-up eye examinations were planned.
Palmer found that the optimal age to detect acute RLF was at age 7-9 weeks and that, for 
optimal ROP detection, the initial examination should not only occur at about 6 weeks 
of life but should also be performed by an ophthalmologist.23 Ideally the fundi should 
at least twice be classified as normal with an interval of 4 weeks before final discon-
tinuation of screening. Palmer et al24 also suggested that, if high-risk infants (<1700gr) 
were discharged or transferred to another hospital prior to an age of 6 weeks, screening 
should be postponed and not be performed at discharge. He reasoned that parents 
could have a false sense of security from a normal eye examination and could wrongly 
decide to refrain from further screening. When this first examination was postponed, the 
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numbers of infants lost to follow up would be smaller and ROP could still be detected in 
time to be able to treat infants with severe disease.
In the late ’60s treatment of acute ROP with Xenon-arc photocoagulation and cryo-
therapy were introduced.25 Cryo-ablation therapy of the avascular retina, freezing from 
the external ocular surface, affecting the sclera, choroid, and the full thickness of the 
retina, emerged as the standard treatment for acute phase ROP in the 1980’s.26
In 1988 the Cryotherapy for Retinopathy of Prematurity Cooperative Group trial (CRYO-
ROP) showed the beneficial effect of cryoablation of the peripheral avascular retina and 
significantly reduced the progression of threshold ROP, which if left untreated carries a 
risk of blindness up to 50%.27 The 10-year follow-up showed that 44.4% treated vs 62.1% 
untreated had visual acuity of 20/200 or worse. At 15 years, the rate of unfavorable 
outcomes was 30% for treated eyes and 51.9% (p<0.001) for eyes that were observed 
without cryotherapy.28;29
In the 1990’s Laser (light amplification by stimulated emission of radiation) therapy 
evolved as the primary modality of treatment, in which a laser is applied through the 
dilated pupil to the internal retinal surface. Compared to cryotherapy, fewer compli-
cations were described. Given the greater ease of treatment with laser a randomized, 
controlled trial was elaborated in 2003 to prospectively assess the effects of early laser 
treatment for ROP: The Early Treatment of ROP (ETROP) study.30 This study confirmed the 
efficacy of treatment for severe ROP and redefined the indications for treatment.31 The 
clock hours and the terminology of threshold and pre-threshold were abandoned and a 
new categorization of ROP was introduced in which ROP was defined in two types.
Also during the mid-1980s, after decades of discussion regarding the nature of the 
pathogenesis and the clinical course of ROP, a group of ophthalmologists represent-
ing 11 countries and sharing a common interest in ROP, decided that an international 
classification of ROP was required. They developed the International Classification for 
ROP (ICROP).32 Later, in 1988, they added a section on the classification of retinal detach-
ment.33
In 2005 the ICROP needed revision as new presentations of ROP occurred in infants with 
GA of 25 weeks or under and the role of the retinal vessels for the decision to treat had 
changed as a result of the ETROP study. An extra stage and a definition of (pre-)plus 
disease were added, clock hours were no longer included.34
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CLASSIFICATION
The revised ICROP uses the following criteria to score ROP:
•	 location	of	retinal	involvement	specified	as	zone	I-III
•	 the	degree	of	peripheral	vascular	abnormalities
 o  stages 1-5, with stage 5 being the most severe (figure 1)
 o  aggressive, posterior ROP (APROP), an aggressive form of ROP, not following the 
classical stages 1-5
•	 plus-	 and	pre-plus	 disease	 to	 describe	 specific	 features	 of	 the	 retinal	 vessels.	The	
designation 'plus' is added to the ROP stage number
Zones to define the location of the disease:
Zone I:   the area within a circle with a radius of twice the distance from the optic disc 
to the center of the macula.
Posterior Zone II: the area within the dotted circle with a radius of three times the dis-
tance from the optic disc to the center of the macula.
Zone II:  extends from the edge of zone I and with the peripheral border the edge of 
a circle with a radius equal to the distance between optic disc and nasal ora 
serrata.
Zone III:  extends from the edge of zone II. It is only entered with certainty when the 
nasal retina is fully vascularized.
The zone that is affected by the disease is important because it reflects the extent of the 
outgrowth of the retinal vessels. The lower the zone, the larger the avascular area result-
ing in the highest risk for severe ROP. Zone I or posterior zone II are therefore associated 
with a bigger chance of progression of disease or need of treatment.35
Figure 1 Retinal zones
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Stages to classify the severity of the disease:
Stage 1:  Characterized by a demarcation line: A thin, flat white line, seen between the 
vascular and avascular retina.
Stage 2:  Characterized by a ridge: an elevation or thickening of the retina in the region 
of the demarcation line.
Stage 3: Characterized by a ridge with extraretinal fibrovascular proliferation.
Stage	4:	 Characterized	by	partial	retinal	detachment	and	subdivided	in;
Stage 4a: Partial detachment not involving the foveal region
Stage 4b: partial detachment involving the foveal region
Stage 5:  Characterized by total detachment of the retina, forming a funnel shape. The 
funnel is divided in an anterior and posterior part, for descriptive purposes. 
And both parts can be open or closed.
   Anterior  Posterior
   Open   Open
   Narrow  Narrow
   Open   Narrow
   Narrow  Open
APROP:  Characterized by neovascular fronts that lay flat on the retinal surface. No 
ridge is seen in these eyes, and yet the AV shunting, which occurs within the 
ridge tissue in more typical ROP, is seen throughout the posterior pole. Ves-
sels are dilated and tortuous in a syncytial pattern. ROP is confined to zone 1 
or posterior zone 2.
    Most critical feature: may progress directly to severe ROP, without interval 
findings typical of stage 1 or 2 ROP.
Pre-plus disease:  A description of an intermediate level of plus disease (pre-plus) be-
tween normal aspect of posterior pole vessels and frank dilation as in 
plus disease.
Plus disease:  Defined as an increased dilation of venules and tortuosity of arteries 
of the retina in at least 2 quadrants in the posterior pole, whether or 
not accompanied by engorgement of iris vessels, pupil rigidity and 
vitreous haze. Plus disease implies that the ROP process is (highly) 
active and progression may be rapid.
Stages 1 and 2 and any other phase without plus disease are usually considered mild 
since most cases resolve spontaneously without major visually disabling sequelae.36 ROP 
with plus disease and stages 3 - 5 are considered severe, as they have a significant risk 
of poor visual outcome. Stage 4a eyes that remain stable usually maintain reasonable 
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vision but progression to stages 4b and 5 (being associated with retinal detachment 
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Figure 2 Photo’s depicting the different stages of ROP
Schematic pictures are published with approval of ROPARD.




From the 16th week of gestation the retinal vessels start growing from the optic disc to 
the periphery of the retina. The retina is fully vascularized at the nasal side at 32 weeks 
and the temporal side around 40 weeks of gestation.37 Infants born prematurely have 
incompletely vascularized retinas with a peripheral avascular zone.38 Two processes 
underlie vascular development. The first process, termed vasculogenesis, involves the 
de novo establishment of a rudimentary vascular plexus, and is completed at 21 weeks 
GA. The second process is termed angiogenesis and involves the development of new 
vessels from already existing vessels and is initiated by 17–18 weeks GA.39 When there is 
a significant disruption in the angiogenesis, ROP may develop.
After premature birth, there is not only a change in oxygenation of the retina but also 
a loss of maternally derived factors that contribute to normal retinal vessel formation.40 
This may compromise normal vascular development.
Retinopathy of prematurity is a biphasic disease, consisting of an initial phase of vessel 
growth retardation called the vaso-obliterative phase, followed by a second phase the 
vaso-proliferative phase. The vaso-obliterative phase is initiated upon birth of the pre-
mature infant. The extra-uterine environment is relatively hyperoxic for the infant, and 
by use of additional oxygen this hyperoxia increases. In response to the elevated levels 
of oxygen, expression of hypoxia-driven angiogenic factors, like vascular endothelial 
growth factor (VEGF) and Erythropoietin (EPO) are downregulated: vessel growth ceases 
and already formed vessels constrict and retract.41
The vaso-proliferative phase usually develops after 32 week GA. Because of maturation 
of the retina, there is an increase in the metabolic activity in the incompletely vascu-
larized areas causing hypoxia. This hypoxia leads to stabilization and translocation of 
hypoxia-inducible factors (HIFs). HIF-1 is rapidly degraded during normoxia, but in 
hypoxic conditions, its half-life is prolonged, promoting its nuclear accumulation. Of the 
hypoxia-inducible factors, HIF-1α is considered the primary hypoxic signaling molecule, 
leading to stimulation of transcription of angiogenic factors like VEGF and EPO that 
stimulate new vessel growth.42 The reduction of HIF-1 is essential for the initiation and 
progression of the first phase of ROP, whereas its increase is essential for the second 
phase.43
VEGF is necessary for normal vascular development and maintenance of growth. Its pro-
duction is oxygen-regulated and is found to be important in both phases of ROP.44 VEGF 
is likely to be the factor with the strongest influence on vascular activity in ROP eyes.45
EPO has a main function in erythrocyte formation in the bone marrow and plays a role in 
angiogenesis, independent of VEGF.45 The exact role of EPO in retinal neovascularization 
is still not well elucidated but it has been reported that it stimulates cell proliferation, 
migration, tube formation and permeability, just like VEGF.46
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Hypoxia stimulates overproduction of VEGF and EPO, inducing angiogenesis that can 
lead to the formation of new vessels of bad quality (neovascularization) at the verge 
of avascularized and vascularized retina, that can regress if adequate oxygenation is 
provided to the avascular retina.
Also other molecules with angiogenic or anti-angiogenic properties appear to play an 
important role either by inter-acting with VEGF or by acting independently as is seen 
with IGF-1.47
Nitric	 oxide	 (NO•)	 and	 nitric	 oxide	 synthase	 (NOS)	 are	 oxidative	 and	 nitro-oxidative	
stress-dependent mediators that are increased in retinal hypoxia. Nitric oxide (NO) is a 
key signaling molecule that mediates neurotransmission, vasodilatation and host cell 
defense.	 NO•	 triggers	 the	 gene	 expression	 of	 several	 angiogenic,	 cell-migration	 and	
proliferation-inducing factors, including VEGF.48
Hypoxic injury increases retinal mRNA and protein expression of endothelial nitric oxide 
synthase (eNOS), leading to increased NO production and, consequently, vasodilatation 
and angiogenesis.49
Maternally derived factors that play a role in the pathogenesis of ROP are insulin-like 
growth factor–I (IGF-I) and omega-3 polyunsaturated fatty acids (PUFA).
Insulin-like growth factor (IGF-I) is produced by the placenta and an important factor 
in normal retinal vascular development.50 Under normal conditions the concentration 
of IGF-I in the foetus increases during the third trimester of pregnancy, but in case of 
preterm birth, IGF-I concentration decreases rapidly, as the placenta can no longer 
supply IGF-I.51 As the infant matures, IGF-I levels slowly increase, and metabolic activity 
of the nonvascularized retina increases, leading to tissue hypoxia. For normal vascular 
development and outgrowth, concentrations of VEGF and IGF-1 need to be in balance 
with each other. If the balance is disrupted ROP can develop (fig 3), if the balance is es-
tablished than regression of ROP can be seen and normal vessel outgrowth can develop.
 
Figure 3 Schematic representation of IGF-I/VEGF control of blood vessel development in ROP.
Adapted from: Hellström et al, Proc Natl Acad Sci USA 2001; 98: 5804-8.
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Another maternally derived factor is PUFA that potently protects against neovascular-
ization. Retinal lipids have a very high content in long-chain poly-unsaturated fatty acids 
(PUFA). The major PUFA’s found in the retina are omega-3 and omega-6. These lipids are 
essential fatty acids. They have to be of exogenous origin since the human body cannot 
synthesize their precursors.48 Omega-3 PUFA is mainly transported in the third trimester 
of pregnancy and infants born before miss that infusion of specific lipid. Deficiency of 
omega-3 PUFA causes retardation of retinal vessel growth.52
It may be evident that a large number of mediators are involved in the pathogenesis of 
ROP. Every step in a better understanding of the complex molecular mechanisms under-
lying the pathogenesis of ROP will hopefully allow the development of new therapies to 
prevent or treat ROP.
ETIOLOGY
The etiology of ROP is multifactorial, but the most important risk factors are birth weight 
and gestational age of the premature born infant.53-57 Other frequently found risk fac-
tors are: length of stay on a neonatal intensive care unit (NICU)58, duration of artificial 
ventilation (AV)59;60, administration of postnatal glucocorticoids59;60, duration of oxygen 
supplementation and fluctuations in oxygen saturation levels.57;61 55 Perinatal infection/
inflammation or sepsis and necrotizing enterocolitis (NEC) are published as a risk factor 
for (severe) ROP.62-66 Another study found that male gender has a significantly increased 
risk to develop ROP.67 More recently published risk factors are hyperglycaemia68;69, slow 
weight gain during the first 3-4 weeks after birth56 or poor growth.70
From the 1940s onwards, the toxity of oxygen in relation to ROP has been studied. 
Hypoxia induced oxidative stress to the developing vessels is not only caused by supple-
mental oxygen but also mediated by the hypoxanthine-xanthine system generating 
oxygen radicals. This causes capillary damage through toxic effects on endothelial cells, 
vaso-obliteration, shunt formation and subsequent neovascularization of vessels.21;71
The role of blood transfusions and the association with the development of ROP has been 
confirmed in several studies.63,72,73 A Dutch cohort study showed that more than three 
blood transfusions, given in the first 4 weeks after birth, increased the risk to develop 
ROP significantly.74 Red blood cell (RBC) transfusions are associated with an increased 
risk for ROP as they increase retinal oxygen levels by an increase in oxygen carrying 
capacity and a decrease in oxygen affinity of the red blood cell. The latter is caused by 
the fact that infants are usually transfused with adult hemoglobin, which has a reduced 
oxygen affinity compared to fetal haemoglobin.75 An additional explanation may be that 
blood transfusions increase the free, non-protein bound iron load. Non protein bound 
iron may react with various intermediates of oxygen. It converts less reactive radicals 
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such as hydrogen peroxide and superoxide to the highly reactive, free hydroxyl radical. 
Free oxygen radicals are assumed to play an important role in the pathogenesis of ROP 
as they cause direct, irreversible damage to the developing retinal vessels by damaging 
the endothelial cell membrane, its mitochondrion and its nucleus.76 An unintended side 
effect of RBC transfusions could be the concomitant administration of IGF-1. Hübler et 
al77 showed that the IGF-1 load in RBC transfusions is equivalent to a single dose of 1 
μg/kg, which is 5-10% of the adult dose. IGF-1 is an important mediator for the devel-
opment of retinal vessels. Hellström et al showed that in a period of rapid increase of 
IGF-1 in combination with high levels of VEGF, rapid growth of new vessels takes place.78 
Therefore, supplemental administration of IGF-1 via RBC transfusions may thus trigger a 
rapid growth of neovascularizations as seen in the development of severe ROP.
Regarding transfusions, infants with twin-twin transfusion syndrome (TTTS) are of 
interest. Due to severe anaemia, donor infants need high numbers of RBC transfusions 
facilitating the development of severe ROP.79
All above mentioned risk factors have in common that they are indicators for the sever-
ity of illness of the infant.55;80
PROTECTIVE FACTORS
A few factors are associated with a reduced risk for ROP, and thus related with a lower 
incidence of ROP: prenatal glucocorticoids, female gender, surfactant and oxygen.67;81
Prenatal glucocorticoids
The beneficial role of antenatal glucocorticoids on the severity of ROP is described by 
Higgins et al.81 Given before birth, maturation of the fetal lung is stimulated, resulting in 
a reduction in respiratory distress syndrome (RDS), associated with decreased morbidity 
and mortality.82;83
Female gender
Darlow et al67 identified gender as a risk factor for ROP finding a significant increase of 
ROP in boys. The study of Binet et al84 found no difference in the rates of ROP between 
the two gender groups. But males had poorer respiratory outcome, were more likely to 
have an adverse neonatal outcome or had a higher mortality than females. They hypoth-
esize that antenatal glucorticoids do not benefit males as much as females.84 Several 
studies describe an advantage in the survival of girls among premature infants suppos-




Respiratory distress syndrome (RDS) is caused by a deficiency or dysfunction of pulmo-
nary surfactant. Surfactant lines the alveolar surface and prevents atelectasis by reduc-
ing surface tension. Its concentration is often decreased or even lacking in the lungs 
of very preterm babies and therefore surfactant replacement therapy has been used 
for the treatment of RDS since the eighties. Beneficial effects on ROP can be explained 
by earlier stabilization of the RDS, less RDS-related morbidity, a decrease in duration 
of supplemental oxygen, a decrease in mean fraction inspired oxygen administration 
and less fluctuations in oxygen saturation. The influence of surfactant therapy on overall 
incidence and the incidence of severe ROP has been investigated. Some studies found 
a decrease in severe ROP, others did not find a protective effect.87-90 To evaluate if the 
timing of administration of surfactant influences mortality and morbidity a Cochrane 
review has been performed.91 Early (within the first two hours of life) versus delayed 
surfactant administration to infants with established RDS requiring assisted ventilation 
showed a decreased risk of acute pulmonary injury (decreased risk of pneumothorax 
and pulmonary interstitial emphysema) and a decreased risk of neonatal mortality and 
chronic lung disease compared to delaying treatment of such infants until they develop 
worsening RDS. No difference was found between early versus delayed surfactant ad-
ministration regarding all stages or stage 3 or more ROP.92-95
Oxygen
Although oxygen in general is considered a risk factor for ROP, the role of oxygen to 
reduce the risk of severe ROP is extensively studied and will be discussed in more detail. 
The Supplemental Therapeutic Oxygen for Prethreshold ROP (STOP-ROP) trial found that 
higher oxygen saturation levels (96-99%) as compared with lower levels (89-94%) did 
not significantly reduce the risk of severe ROP, but a subgroup analysis suggested that 
infants with prethreshold disease without plus disease could benefit from these higher 
levels.96 Other studies61;97;98 describe that lower oxygen saturation levels during the first 
weeks of life decrease the incidence of ROP and of severe ROP, but are also associated 
with a higher mortality. To answer the question whether infants should be kept at low 
or high oxygen saturation in the period after birth, five multicenter randomized trials 
were recently analyzed in the Neoprom study.99 The trials included were the SUPPORT 
(Surfactant, Positive Pressure and Pulse Oximetry Randomized Trial)100;101, the three 
BOOST trials (Benefits of Oxygen Saturation Targeting) from the UK, Australia and New 
Zealand102, and the Canadian Oxygen Trial (COT).103 A total of 4911 infants with GA < 28 
weeks were randomized to low (85–89%) or high oxygen saturation (91–95%) in the first 
24 hours after birth and relative risks (RR with 95% confidence intervals) were calculated 
for mortality and morbidity. A RR>1.0 favored high oxygen saturation. The primary 
outcome of the SUPPORT was severe ROP  /  death before discharge, for the BOOST II 
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death or severe disability at 18-24 months and for the COT death before 18 months 
or	severe	neurosensory	outcome.	The	RR	for	mortality	(1.41;	114-174)	and	necrotizing	
enterocolitis	(1.25;1.05-1.49)	was	significantly	increased	and	for	severe	ROP	(0.74;0.59-
0.92) significantly decreased in low versus high oxygen saturations. No differences were 
found for bronchopulmonary dysplasia, patent ductus arteriosus and injury to the brain.
The conclusion of the Neoprom meta-analysis was that in infants <28 weeks low satura-
tion targets (85–89%) until 36 weeks postmenstrual age (PMA) are associated with more 
deaths and more NEC and higher saturation targets (91–95%) are associated with more 
ROP. Based on these figures the final advice of the Neoprom is to target SpO2 at 90-95% 
in infants born before 28 weeks until 36 weeks PMA, although this might result in more 
infants developing ROP.
NATURAL COURSE
ROP is in general a symmetrical disease and both eyes are usually evenly affected. In 
most infants ROP regresses spontaneously. When ROP develops, it normally progresses 
with one stage per week, except for APROP.
In studies two different definitions for the age of an infant are used:
•	 PNA:	post	natal	age:	number	of	days	or	weeks	after	birth,	and
•	 PMA:	post	menstrual	age:	gestational	age	plus	the	days	or	weeks	after	birth
The first signs of ROP develop between 5–7 week post natal age (PNA).
In the Natural History Study of Fielder104 the PMA at which ROP developed ranged from 
29.7 to 45.0 weeks. Furthermore it is known that severe ROP does not develop before 31 
weeks post menstrual age (PMA) or 4-5 weeks PNA.105,106
Comparing the outcomes of the CRYO-ROP and ETROP study onset of the different 
stages of ROP appears to be consistent: stage 1 at 34.3 vs 34.1 weeks, stage 2 at 35.4 vs 
35.1 weeks, stage 3 for both at 36.6 weeks and plus disease at 36.3 vs 36.0 weeks PMA.107
Larsson et al105 found a PMA for severe ROP of 36.1 (32–44) weeks. Hains et al108 found a 
mean PNA at first diagnosis of stage 3 ROP at 10.8 (4–24.7) weeks and at mean PMA 36.6 
(30.8–51.7) weeks.
In most cases, spontaneous regression of ROP usually occurs within 15 weeks from 
onset109 without serious secondary damage in eyes with stages 1, 2 and early stage 3 
ROP, while serious visual impairment or blindness results from progression to retinal 
detachment (stage 4 or 5) or severe distortion of the macular area.110 The incidence of 
spontaneous regression of ROP stage 1 was between 86.7 - 85%, stage 2 between 57.1- 
56% and stage 3 between 5.9-6.0%.
With vascular changes in zone III regression was detected in 95-100%, in zone II in 45-




Worldwide different screening criteria are used.
The guideline of the UK developed by the Royal College of Pediatric & Child Health, 
recommends screening for all infants with a birth weight ≤ 1,500 g or a gestational age 
of ≤ 31 weeks.113
The American guideline advises to screen all infants with a birth weight (BW) <1.500 g or 
a gestational age (GA) ≤ 30 weeks, as well as selected infants between 1.500 and 2.000 
g and selected infants > 30 weeks GA with an unstable clinical course, including those 
requiring cardiorespiratory support and those who are believed to be at high risk for 
ROP by their attending pediatrician or neonatologist.114
The Canadian guideline recommends screening of infants with a BW ≤ 30 weeks or BW 
≤ 1500 g (www.eyesite.ca).
The Guideline of Germany uses the inclusion criterion of GA < 32 weeks or when GA is 
unsure, a BW < 1500 g.115 Infants with a GA between 32-36 weeks and > 3 days in need 
of extra oxygen administration should also be screened.
The screening criterion of Sweden is GA ≤ 31 weeks.105 The inclusion criteria for screen-
ing in the Netherlands, as defined in 1997, were all infants with GA<32 weeks and/or 
BW< 1500 g and all those needing >40% oxygen for more than 3 days.
The timing for follow-up screening is grossly the same in all the aforementioned coun-
tries:








When there is no risk for the development of vision-threatening ROP, screening can be 
discontinued. If the retina is fully vascularized ROP can no longer develop. When the 
vessels have grown to zone III the chance of developing severe ROP is minimal.
According to the UK guideline screening may be stopped when apparent regression is 
seen. The definition of regression has been described in the ICROP.34 The German guide-
line advises to end the screening at 40 weeks PMA. When the condition of an infant 
deteriorates, a reactivation of ROP can be seen and screening should be restarted.
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Screening models
Several attempts are made to define risk factor models predicting the chance to develop 
ROP with the ultimate goal to focus screening on those infants that are really at risk to 
develop ROP and reduce the overall number of screening examinations.




Four ROP screening models based on postnatal course were developed: WINROP, 
ROPScore, Cumulative Illness Severity (CIS) and a model based on Clinical Risk Index for 
Babies (CRIB) score, multiple birth, race and gender.86;116-119
WINROP
The WINROP116 model is an algorithm using postnatal weight measurements, as a tool 
for the prediction of ROP. Weight measurements are entered into the WINROP database, 
which triggers an alarm for an abnormal weight gain rate. Infants were classified into 
categories of no alarm (unlikely to develop type 1 ROP) and alarm (at risk for developing 
type 1 ROP). Use of WINROP requires that an infant has:
- gestational age less than 32 weeks at birth,
- weekly weight measurements,
- physiologic weight gain, and
- absence of other pathologic retinal vascular disease.
Studies to evaluate the efficacy of WINROP in predicting the need for treatment have 
been done in different countries: in China the predictive score was 87.5%120, in Mexico 
84.7%121 and in a Swedish cohort 96%.122 A retrospective cohort study in South East 
Scotland emphasizes that WINROP should be used as recommended i.e. using weekly 
birth weights. They found a sensitivity of 73% when missing BW data were extrapolated 
and a sensitivity of 87% when BW had been measured weekly.123
ROPScore
The ROPScore model is based on risk factors for the onset of ROP and includes data on 
BW, GA, weight gain proportional to BW measured at 6 weeks of life, the use of oxygen 
in mechanical ventilation and the need for blood transfusions. ROPScore is calculated 
automatically when data are inserted. Points are given if risk factors are present. If the 
score is above 14.5 there will be a higher risk to develop severe ROP than in infants with 





The third model, Cumulative Illness Severity118, works with cumulative neonatal illness 
severity and illness severity fluctuation as predictors of progression from moderate 
to severe ROP. It is measured using daily Scores for Neonatal Acute Physiology (SNAP) 
for the first 28 days of life, and illness severity fluctuation as assessed by summing up 
changes between daily SNAP scores. The physiology-based SNAP score is calculated 
from 34 biological parameters including vital signs and laboratory values. Cumulative 
SNAP score for the first 28 days of life (SNAP28) was calculated by addition of daily SNAP 
scores for each subject. The cumulative SNAP score, turned out to be an independent risk 
factor for progression from moderate to severe ROP, but after adjustment for different 
risk factors, it did not enhance assessment of risk for ROP. As it is also time consuming to 
execute, CIS seems less applicable as easy screening tool.
CRIB
The Clinical Risk Index for Babies score (CRIB)86 estimates illness severity using data 
collected in the first 12 hours after birth. The parameters are birth weight, gestational 
age, congenital malformation, maximum base excess and maximum and minimum ap-
propriate FiO2 (fraction of inspired oxygen). Yang et al investigated 5 models based on 
CRIB score, multiple birth, race and gender. Their primary outcome variable was ROP 
warranting surgery and they found that nonblack race, male gender, and higher CRIB 
illness severity scores were significant predictors. They also excluded BW and GA from 
the CRIB score and found that the CRIB-score remained a highly significant independent 
predictive factor for ROP warranting surgery.
All these prediction models need further validation before they can possibly replace 
established screening programs. They can however help to reduce the frequency of 
screening exams in low risk infants.
TREATMENT
The goal of treatment is to decrease the production of angiogenic factors and to stop 
retinal neovascularization by inactivation of the avascular peripheral retina.
The Cryotherapy for Retinopathy of Prematurity Cooperative Group trial (CRYO-ROP) 
showed the beneficial effect of cryoablation of the peripheral avascular retina.
Two types of ROP were distinguished, namely threshold and pre-threshold ROP.
Threshold ROP was defined as at least 5 contiguous or 8 cumulative clock hours of stage 
3 ROP in zone I or II in the presence of plus disease. Pre-threshold ROP was defined 
in relation to the location of the disease, for zone I: any stage less than threshold and 
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for zone II: stage 2 ROP with plus disease, or stage 3 ROP of any amount without plus 
disease, or stage 3 ROP with less than 5 contiguous or 8 cumulative clock hours with plus 
disease. When lasertreatment started to replace cryotreatment the Early Treatment of 
ROP (ETROP) study was performed which confirmed the efficacy of treatment for severe 
ROP and redefined the indications for treatment.30;31 The clock hours and the terminol-
ogy of threshold and pre-threshold were abandoned and a new categorization of ROP 
was introduced in which ROP was defined in two types, where type 1 needed immediate 








The ETROP study was a randomized, prospective multicenter trial comparing the safety 
and efficacy of earlier vs. conventionally timed ablation of the peripheral retina for the 
management of moderate to severe retinopathy of prematurity (ROP). Infants with birth 
weights <1251 g were screened and the total sample size for the randomized trial consist-
ed of 401 infants. Only prethreshold eyes that had a high risk of an adverse outcome were 
randomized for early treatment. The primary outcome measure was rating visual acuity 
measured by Teller acuity card. The secondary outcome measure was retinal structure, 
assessed by ophthalmological examinations conducted at 6 and 9 months post-term.
At six year follow-up an unfavourable outcome was seen in type 1 ROP with early treat-
ment in 25.1% and in type 1 ROP treated at threshold in 32.8% (p < 0.001). A visual acuity 
(VA) worse than 20/200 was found in 24.7% for those treated at pre-threshold vs 29% for 
those treated at threshold (p=0.15).124
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To calculate improved vision after treatment according to ETROP criteria vs CRYOROP 
criteria one has to compare no treatment vs treatment. For the CRYO-ROP study cryo-
therapy vs no treatment meant 44.4 vs 62.1% = 17.7% improved vision. In the ETROP 
study no comparison was made between no treatment and laser as this was considered 
unethical. So the improved vision in this study is the difference between 25.1% vs 32.8% 
resulting in 7.7% less infants with VA < 20/200.
The total improved vision is determined by summing the results of CRYO-ROP and 
ETROP, which would result in 17.7 + 7.7= 25.4% improved vision after early treatment.
With the ETROP classification more emphasis came on the presence of (pre)plus disease, 
and the extent of avascularity, defined by zone. Nowadays this is the most important 
treatment algorithm.
With laser and cryo-therapy the treated areas of the retina are permanently damaged 
and lose their function. Different new possibilities for treatment are being investigated, 
that might save peripheral retina, the main being treatment suppressing VEGF produc-
tion by intraocular injections.
To study the efficacy of anti-VEGF drugs, preclinical studies have used models of oxygen-
induced retinopathy (OIR) that develop hypoxia-induced intravitreal neovascularization 
(IVNV).
The Bevacizumab Eliminates the Angiogenic Threat of ROP (BEAT-ROP) study is the first 
prospective, controlled, randomized, multicenter trial to assess intravitreal bevacizumab 
monotherapy for zone I or zone II posterior stage 3+ ROP compared to conventional la-
ser.125 The primary ocular outcome was recurrence of retinopathy of prematurity in one 
or both eyes requiring retreatment before 54 weeks’ postmenstrual age. Recurrence of 
ROP was 4% in the bevacizumab group vs 22% in the laser group (p=0.002). A significant 
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treatment effect was found for zone I retinopathy of prematurity (P=0.003) but not for 
zone II disease (P=0.27). The main comment on the study is that laser treatment was not 
performed according to ETROP criteria, which is common practice nowadays. This might 
have biased outcomes of laser treated eyes.
Because of this positive result on the short term, other studies have been conducted. 
Concerning reports of persistent peripheral avascular retina (AVA), recurrent IVNV, and 
stage 5 ROP retinal detachment, even 1 year following treatment, in some of these 
treated eyes have been published.126-129 Furthermore it has been reported that anti-VEGF 
agents are still measurable in the systemic circulation 8 weeks after treatment possibly 
causing adverse effects on other developing organs such as kidney, lung and brain.130
In an animal study, it was established that even in a controlled model in which external 
conditions (as for example oxygen levels, body weight, species, number of pups) were 
kept constant, variability in responses could be seen. The signaling effects following 
anti-VEGF treatment are complicated by the effects on different retinal cells, timing of 
anti-VEGF treatment, and dosing. It was concluded that in a human preterm infant the 
variability is even greater, making it difficult to determine the correct dose. They also 
found that weight gain was impaired in the pups who received anti-VEGF treatment.131
All these side effects of Anti-VEGF treatment therefore call for further investigation in 
multicenter, randomized controlled trials. Until then, administration of these drugs 
should only be done by experienced centers and after written informed consent of the 
parents. After all, we have to keep in mind that VEGF is necessary for normal retinal 
vessel development.
OUTLINE OF THIS THESIS
Changes in neonatal care have increased the survival of preterm infants and decreased 
the age at which preterm born infants are kept alive, resulting in an increasing number 
of infants at risk for ROP. Therefore up-to date information on incidence of ROP and 
visual impairment (VI) due to ROP was needed.
In Chapter 2 the incidence of VI due to ROP and concomitant disabilities in preterm 
neonates born between 2000 and 2009 in the Netherlands is reported. Data were re-
trieved from the Dutch Institutes for the visually impaired. Outcomes were compared 
with previous Dutch studies resulting in an overview of more than 30 years to determine 
if changes in neonatal care resulted in a different outcome in incidence of ROP and 
concomitant disabilities.
The last study on ROP incidence in the Netherlands was conducted in 1952 by Von Win-
ning.132 As no obligatory national registry for ROP exists, a deficient insight in incidence 
and risk factors for ROP exists, leaving several Dutch cohort studies as the only source of 
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information.60;89;133 A Netherlands Perinatal Registry (PRN) is available, which is used by 
neonatologists and pediatricians to improve the quality of health care through insight 
into the perinatal care process and its outcomes. A section on ROP is included, but is often 
poorly filled out because correct information on ROP is not known or the PRN document 
is completed in a phase where information on ROP screening is not available yet.
In the Netherlands an increasing number of hospitals provides care to premature born 
infants, facilitating earlier transfer. Initially most premature infants were admitted to one 
of ten neonatal intensive care units (NICUs). Nowadays as soon as infants are respiratory 
and circulatory stable and intensive care is no longer required, they are transferred to 
one of 16 high care centers (HC) or 77 regional centers (RC).
Before, the initial screening examination was performed by ophthalmologists in a NICU. 
They screened a large amount of infants and were therefore very experienced in ROP 
screening. This resulted in careful selection of high risk infants whose transfer to a HC 
or RC was postponed. Nowadays, transfer from a NICU to a HC or RC often takes place 
before the first ROP screening has been performed. Therefore, ROP screening has to be 
performed by an increasing number of Dutch ophthalmologists who have less overall 
exposure to ROP patients due to a limited number of patients. In addition, transfer of a 
child can result in unintended loss of clinical information concerning the neonate as well 
as loss of data concerning start or follow-up of ROP screening.
All the above mentioned issues called for the necessity of an updated insight in incidence 
and risk factors for ROP, adherence to the screening protocol and treatment policy in 
our country. Therefore a prospective nationwide inventory on ROP was initialized: the 
NEDROP study. With these up-to-date data, our final aim was to develop a new quality 
guideline for screening and treatment that would fit the Dutch situation.
The NEDROP-study
In 2008 we requested pediatricians and neonatologists to report all infants born in 
2009 that complied with the inclusion criteria of the then prevailing National Guideline. 
Furthermore we recruited the screening ophthalmologists to report all children they 
screened for ROP born in 2009. A code was developed to enable anonymous data trans-
mission and coupling to the National Perinatal Registry (PRN) to link risk factors for ROP 
with ophthalmological data.
Permission of the Medical Ethical Committee (METC) in Leiden was obtained. Their deci-
sion was as follows: ‘Since no persons are subjected to a treatment or are required to behave 
in a certain manner, this proposal does not require a full review by the Medical Ethics Com-
mittee according to the WMO (Medical Research involving Human Subjects Act). To protect 
the privacy the processing of personal data is performed according with the Wbp (Personal 
Data Protection Act).’
30 Chapter 1
All personal data were coded and later on further depersonalized by numbering. This 
discharged us from the obligation to ask permission of METC’s of all participating hospi-
tals, enlarging the chance of success enormously.
At the start of this study the active guideline in the Netherlands dated from 1997. 134 
The screening criteria included infants with GA < 32 weeks and / or a BW < 1500 grams 
and /or preterm infants treated with more than 40% oxygen for more than 3 days. Initial 
screening should be between 5–6 weeks of life (PNA).
Based on these screening criteria we calculated that approximately 1650 premature 
infants per year would comply and were eligible to enter the NEDROP study. The results 
of the NEDROP study are reported in chapter 3, 4 and 5. Chapter 3 reports data on the 
incidence, screening schedules, treatment, transfers and logistics of ROP in the Neth-
erlands. Chapter 4 provides insight in the risk factors found for ROP after coupling the 
NEDROP database to the PRN database.
With all these data we acquired a good overview of the current situation in our country. 
As screening for ROP is costly, discomforting for the neonate and time-consuming for 
the ophthalmologist, the screening guideline was further evaluated. A national ROP 
guideline working group investigated whether a reduction of our inclusion criteria for 
screening was possible, on the pre-condition that no infants with severe ROP would 
be left out. Whether a modification of our national screening guideline is justified is 
described in Chapter 5. Based on figures from the NEDROP study a cost-effectiveness 
study was performed, the most efficient strategy is calculated in Chapter 6. Chapter 7 
is a case report of two twin pairs with severe retinopathy of prematurity in twin-twin 
transfusion syndrome (TTTS) after multiple blood transfusions.
Finally a summary of the results is presented and conclusions and recommendations for 
the future are formulated.
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ABSTRACT
Aim To determine the incidence of visual impairment (VI) caused by retinopathy of 
prematurity (ROP) and concomitant disabilities in preterm neonates born between 2000 
and 2009 in the Netherlands.
Methods Data were retrieved from the Dutch institutes for the visually impaired. They 
were compared with similar Dutch studies conducted in 1975-1987, 1986-1994 and 
1994-2000.
Results Records of 42 infants with VI due to ROP were included. A gradual decrease 
of gestational age and birthweight but an increase of duration of artificial ventilation, 
supplemental oxygen administration, bronchopulmonary dysplasia, developmental 
delay and behavioural abnormalities was found. Compared with the previous study 
(1994-2000), significantly fewer children were visually impaired due to ROP (1.84 per 
100,000 live births/year vs 3.93 per 100,000 live births/year, p<0.000), the incidence of 
complete blindness decreased from 27.5% to 7.1% (p<0.05) and more children were 
treated (66.7% vs 56.9%, NS). The incidence of concomitant disabilities was high and did 
not differ greatly from the previous study.
Conclusion This was a retrospective study showing a significant decrease in VI due to 
ROP in the Netherlands. Changes in neonatal care practices did not result in a decrease 
in the incidence of concomitant disabilities. More children were treated for ROP, but 33% 
were not treated.
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INTRODUCTION
Retinopathy of prematurity (ROP) is still one of the most important causes of partial 
sight or blindness in premature infants. In developed countries, ROP accounts for 5.5% 
to 20% of childhood blindness.1-4 The pathogenesis of ROP is multifactorial, but the 
most significant risk factors for ROP are low gestational age (GA) and low birthweight 
(BW).5-7 Changes in neonatal care over the past two decades have increased the survival 
rate of very small and very preterm infants. This was due to introduction of surfactant, 
increased use of antenatal steroids, resuscitation of infants with lower GA, improved 
nutrition and prophylactic use of indomethacin. Due to this increased survival rate, 
many very preterm infants are at risk not only of visual impairment (VI) caused by ROP 
but also of nonvisual disabilities.8-10 Apart from changes in neonatal care practices, there 
have been changes in management of ROP. To reduce the number of adverse outcomes, 
treatment in the pre-threshold phase was introduced, resulting in an increased number 
of infants treated for ROP.11-13 From 1952 onwards, five surveys were carried out in the 
Netherlands to calculate the number of children visually disabled due to ROP per 100 000 
live	births	per	year:	3.24/100	000	from	1952	to	1964	(Schappert-Kimmijser;	survey	1),14 
2.89/100	000	from	1961	to	1973	(van	de	Pol;	survey	2),15 4.22/ 100 000 from 1975 to 1987 
(Cats	and	Tan;	 survey	3),16	 5.49/100	000	 from	1986	 to	1994	 (Schalij-Delfos;	 survey	4)17 
and	3.85/100	000	from	1994	to	2000	(Termote	et	al;	survey	5).18 The last three surveys 
also included an inventory of concomitant disabilities, showing a marked increase in 
developmental and behavioural abnormalities. To monitor trends and to determine the 
incidence of VI caused by ROP, as well as the incidence of associated disabilities in these 
high-risk, vision-impaired children born between 2000 and 2009, a retrospective study 
was performed (survey 6). Data from the last three surveys were used for comparison, 
resulting in an overview of more than three decades.
PATIENTS AND METHODS
Due to privacy regulations and lack of an obligatory registry for children with VI in the 
Netherlands, access to patient data is limited. Therefore, data retrieval was only possible 
by collecting the records of all infants with a registered diagnosis of ROP who are known 
at one of the Dutch institutes for the partially sighted and blind. This information was 
obtained by one investigator (AJvS). For comparison, the same neonatal and ophthalmo-
logical data as in the previous surveys were collected: GA, BW, visual acuity, treatment for 
ROP, sex, multiple birth, incidence of bronchopulmonary dysplasia (BPD) and duration 
of supplementary oxygen administration, artificial ventilation (AV) and admission to the 
neonatal intensive care unit (NICU). With regard to concomitant disabilities the same 
42 Chapter 2
definitions and classifications as described by Termote et al were used.13 We considered 
children to have multiple disabilities when they had VI caused by ROP plus one or more 
of the concomitant disabilities that were listed, excluding BPD as pulmonary function 
usually improves through the years.
To define VI, the recommendations of the International Association for Prevention of 
Blindness (IAPB) were used (World Health Organization, 1984).19 Due to limitations in 
data collection, information on stages of ROP was unreliable and therefore again ex-
cluded. As the number of infants with cerebral VI increased over the last decade and 
became the most important cause of VI in prematurely born infants,20 data on cerebral 
VI were collected for this survey. However, they could not be compared with the pre-
vious studies. Data on the Dutch birth rate were obtained from the Central Bureau of 
Statistics (CBS). Survival rates of premature infants according to GA were collected from 
the Netherlands Perinatal Registry (PRN).
Data collected for this study (2000-2009) were compared with data from the previous 
study (1994-2000). In addition, data from the four surveys conducted from 1975 onwards 
were compared to identify and evaluate trends in treatments and outcomes.
Statistical analysis
Clinical data from the four surveys (presented in table 1) were evaluated using the inde-
pendent samples t test. The Poison regression was used to perform calculations on data 
on VI caused by ROP in relation to Dutch birth rates, and the c2 test was used for all other 
data. Differences with a p value of <0.05 were considered significant. As all children with 
Table 1 Neonatal data of infants with visual impairment caused by ROP in four consecutive periods in the 
Netherlands.
Period / survey # 1975-1987 / 3 1986-1994 / 4 1994-2000 / 5 2000-2009 / 6
No. Infants 76 87 51 42
Male (%) 47 58 59 74
Mean gestational age (wks)¹ 28.7 ± 2.7 27.5 ± 2.5 27.7 ± 2.4 27.4 ± 2.0
Mean birth weight (gr)² 1128 ± 331 1071 ± 385 942 ± 306 912 ± 385
Multiple birth (%) 18.9 20.7 31.4 31.0
Supplemental O₂ 
administration (days)³
43.2 ± 40.7 78.6 ± 88.8 83.2 ±81.6 81.8 ±78.4
Artificial ventilation (days)4 13.3 ± 22.0 27.6 ± 27.7 24.6 ±16.6 25.3±17.5
Admission to NICU (days)5 - - 92.1 ± 58.2 97.2 ± 71.1
¹ column 1 vs column 2 p= 0,004, 1 vs 4 p=0.004, 2 vs 3, 3 vs 4 and 2 vs 4 ns
² column 1 vs 2 ns, 1 vs 3 p=0.001, 1vs 4 p=0.003, 2 vs 3 p=0.032, 3 vs 4 ns, 2 vs 4 p=0.03
³ column 1 vs 2 p=0.003, 1 vs 3 p=0.005, 1 vs 4 p =0.004, 2 vs 3, 3 vs 4 and 2 vs 4 ns
4 column 1 vs 2 p=0.0009, 1 vs 3 p=0.004, 1 vs 4 p=0.004, 2 vs 3, 3 vs 4 and 2 vs 4 ns
5 column 3 vs 4 ns
The incidence of visual impairment and concomitant disabilities 43
2
VI due to ROP were studied in the subsequent periods, trends could be determined even 
though the separate values failed to reach significance.
RESULTS
Records of 43 children with VI caused by ROP were found. Informed consent was ob-
tained from 42 parents. No additional infants born between 1994 and 2000 (survey 5) 
registered with the diagnosis of ROP were found during survey 6.
General data and neonatal data from infants diagnosed with ROP in four consecutive 
periods in the Netherlands are presented in table 1.
Compared with the previous study (1994-2000) no significant differences were found. 
However, a gradual decrease of mean GA and BW over the years was seen. For supple-
mental oxygen and AV a significant increase was found between surveys 3 and 4, but 
there were no significant changes after the mid 1980s. Not all infants from surveys 3 
and 4 were admitted to a NICU, so admission days to a NICU were only analysed for the 
fifth and sixth survey periods, for which there was no significant difference. Although 
no significant differences were found in clinical data of children from the present study 
compared with the previous study, the proportion of infants with VI caused by ROP in 
relation to Dutch birth rates decreased significantly (table 2).
The average incidence of VI due to ROP is presented column 3 is the result of the fraction 
of the absolute number of individuals with ROP sequelae (column 1) and the absolute 
number of individuals born during the study period (column 2). The average incidence 
of VI due to ROP shows a decrease from the early 1990s.
A decline can be seen starting in the mid 1990s. The incidence of VI due to ROP de-
creased in the period 1994-2000, but failed to reach significance when compared with 
the period 1986-1994 (p=0.07). Comparing our study to surveys 4 and 5 a significant 
Table 2 Visual impairment caused by ROP in relation to Dutch birth rates.
Period / Number No. ROP sequelae No. live births x 105 * ROP sequelae / 100.000 live births
1952 – 196414 (survey 1) 100 30.9 3.24
1961 – 197315 (survey 2) 89 30.8 2.89
1975 – 198716 (survey 3) 97 23.0 4.22
1986 – 199417 (survey 4) 79 14.4 5.49
1994 – 200018 (survey 5) 46 11.7 3.93
2000 – 2009 (survey 6) 32 17.4 1.84
*Central Bureau of Statistics for the Netherlands
The average incidence of VI due to ROP is presented column 3 is the result of the fraction of the absolute 
number of individuals with ROP sequelae (column 1) and the absolute number of individuals born during 
the study period (column 2). The average incidence of VI due to ROP shows a decrease since the early 1990s.
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decrease in the incidence of VI caused by ROP was found (p=0.000 for both surveys). 
More specific data on visual acuity are presented in table 3.
In the current study there were 32 of 42 infants (76.2%) with VI, compared with 46 of 51 
children (90.2%) in survey 5, representing a non-significant decrease. In more detail, our 
survey shows a significant decrease in the number of completely
blind	children	due	to	ROP	compared	with	the	previous	period	(7.1%	vs	27.5%;	p=0.012),	
as well as a significant increase in children who did not fulfill the WHO criteria for VI at 
the	time	of	inclusion	in	this	study	(23.8%	vs	9.8%;	p=0.043).	Eight	children	(19%)	were	
diagnosed with cerebral VI: two not partially sighted or blind, four partially sighted, 
one socially blind and one practically blind. The number of children who were treated 
for ROP increased significantly since survey 3, but there was no significant increase 
between surveys 5 and 6. Infants were treated with laser (n=16), cryotherapy (n=1), 
laser + cryotherapy (n=2), cerclage (n=1), cerclage + laser (n=1), cerclage + cryotherapy 
(n=1), vitrectomy + lensectomy (n=2), vitrectomy + laser (n=2), vitrectomy + laser + 
lensectomy (n=1) or bevacizumab (n=1). The most commonly used therapy was laser 
treatment (79%). Fourteen infants (33.3%) in the present study had not been treated 
versus 22 (43.1%) in the previous study. Four of the untreated children in this study had 
a final visual acuity >0.3 in at least one eye.
Comparing the incidence of concomitant disabilities in infants with ROP, no significant 
changes were found except for epilepsy (p=0.007) (table 4).
In the previous study a significant increase in behavioural abnormalities was seen, but 
this tendency did not extend to the current study. A gradual increase of children with 
BPD, developmental delay and hearing deficit were observed, but differences did not 










No. Infants 76 87 51 42
Visual acuity unspecified 5.1%
Not partially sighted or blind (VA>0.3)+¹ 2% 10.3% 9.8% 23.8%
Partially sighted (VA 0.1 – 0.3) 34.3% 31.0% 25.5% 38.1%
Socially blind (VA < 0.1 - ≥ 1/60) 12.1% 10.3% 11.8% 14.3%
Practically blind (VA < 1/60 – LP) 8.1% 21.8% 25.5% 16.7%
Completely blind (VA = 0)² 38.4% 26.4% 27.5% 7.1%
Treatment of acute ROP³ 24.%% 43.9% 56.9% 66.7%
+ = infants with unilateral blindness and infants whose vision is expected to deteriorate in the future
LP= light perception
VA= visual acuity
¹ column 1 vs4 p= 0.000, 2 vs 4 p= 0.043
² column 1 vs 4 p=0.000, 2 vs 4 p=0.010 and 3 vs4 p=0.012
³ column 1 vs 2 p=0.013, 1 vs 3 p=0.000, 1 vs 4 p=0.000, 2 vs 4 p=0.014
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reach statistical significance. The number of infants with neurological impairment and a 
multiple disability increased significantly between surveys 3 and 4 but was stable after 
this. When the population was subdivided for GA, the incidence of VI caused by ROP 
based on the estimated number of survivors, as well as the incidence of concomitant 
disabilities	 in	surveys	5	and	6,	was	highest	 in	children	born	under	30	weeks;	 the	 inci-
dence of VI increased as GA decreased (table 5). The five infants with unilateral blindness 
(n=1) or visual acuity >0.3 (n=4) were also included in this analysis because this was also 
done in the previous studies.
The percentage of children with concomitant disabilities was again high in this survey, 
but did not differ greatly from survey 5. In survey 5 there were 35 children with concomi-
tant disabilities (68.6%) versus 31 (73.8%) in our survey.
Table 4 Concomitant disabilities in infants with visual impairment caused by ROP in four consecutive peri-










No. Infants 76 87 51 42
BPD¹ 26.3 45.9 60.4 78.3
Behavioral abnormalities and problems² 9.2 21.8 46.9 40.0
Epilepsy³ 5.3 6.9 16.3 0
Hearing deficit4 5.3 2.3 8.2 12.5
Developmental delay5 35.5 47.1 52.9 65.0
Neurological handicaps6 30.3 49.4 45.1 42.5
Multiple disabled7 39.5 58.6 68.2 66.7
¹ column 1 vs 2 p=0.009, 1 vs 3 p=0.000, 3 vs 4 p= 0.016
² column 1 vs 2 p= 0.028, 1 vs 3 p= 0.000, 1 vs 4 p= 0.000, 2 vs 3 p= 0.000, 2vs 4 p= 0.027, 3 vs 4 ns
³ column 1 vs 3 p= 0.049 and 3 vs 4 p=0.007
4 column 2 vs 4 p=0.024
5 column 1 vs 4 p=0.003
6 column 1 vs 2 p=0.013
7 column 1 vs 2 p=0.015, 1 vs 3 p=0.0011 vs 4 p=0.001
Table 5 Visual impairment caused by ROP in relation to estimated number of survivors and concomitant 
disabilities.
GA (wks)













24 – 25 10.4 (11) 12.5 (11) 3.1 (9) 2.4(10) 67 (6) 70 (7)
26 – 27 3.3 (40) 4.3 (36) 1.3 (23) 0.9(19) 65 (15) 79 (15)
28 – 29 0.8 (26) 0.4 (10) 0.3 (10) 0.2(9) 80 (8) 78 (7)
30 – 31 0.2 (13) 0.2 (8) 0.1 (6) 0.03(2) 66 (4) 50 (1)
>32 - <37 0.01 (12) 0.01 (7) <0.001 (2) <0.002 (2) 100 (2) 50 (1)
* Numbers of estimated survivors were derived from the Netherlands Perinatal Registry
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DISCUSSION
We performed a retrospective study on the incidence of VI due to ROP in preterm infants 
born between 2000 and 2009 in the Netherlands. The incidence presented in this study 
must be considered as a minimum incidence because there is no obligatory national 
registry for VI, children may be missed and there is always a possibility that children 
born in the study period will become visually impaired at a later age. However, the same 
caveats apply to earlier studies and no additional infants from the previous periods were 
found during our current search. Data were compared with three earlier Dutch studies 
starting in 1975 (surveys 3, 4 and 5), thus providing an overview of more than 30 years.
Over the years there has been an increase in the survival rate of smaller and more im-
mature infants due to changes in neonatal care practices.21 From 1975 until the present 
time mean GA and BW of infants with VI due to ROP in the Netherlands has gradually 
decreased. Although we found no significant changes in neonatal data in infants with 
VI in the present study compared with the previous study of Termote et al18, we found a 
decrease in VI due to ROP. It seems reasonable to assume that improvement in neonatal 
care might contribute to a better visual outcome in these preterm neonates. An impor-
tant limitation is that we were unable to gain detailed information about the neonatal 
period. From other Dutch studies covering approximately the same period we can learn 
more about general changes that have taken place. Two Dutch cohort studies from 
Hoogerwerf et al22 and Groenendaal et al23 demonstrated an improvement in outcome. 
Groenendaal et al analysed two cohorts of inborn preterm neonates (1997-2001) and 
(2002-2006) with a GA of 25-29.9 weeks and found an improved survival rate but no 
increase in the number of infants treated for severe ROP. The study from Hoogerwerf et 
al focused on changes in the incidence and risk factors responsible for the development 
of ROP and compared two cohorts of premature infants born in the time periods of 
1991-1995 and 2001-2005.
They found an increase in the use of antenatal steroids and surfactant and a decrease 
in the duration of AV, supplemental oxygen administration and NICU admission, as well 
as a decrease in incidence of ROP. Most of these changes were not reproducible in our 
study. However, we included only those infants that were referred to one of the Dutch 
institutes for the visually impaired and were supposedly the most critically ill neonates. 
We speculate that more subtle improvements in neonatal care are responsible for the 
decrease in the incidence of VI caused by ROP and of completely blind children. Further-
more, there was an increase in infants treated for ROP (from 56.9% to 66.7%). The Early 
Treatment of Retinopathy of Prematurity criteria (ETROP) were introduced in the early 
phase of this survey resulting in a larger number to treat and an expected reduction of 
adverse outcomes.3,11,12 In addition, the study of Termote et al18 resulted in a campaign 
for more awareness of necessity to treat timely and for potential visual problems on the 
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long term. Earlier referral to the Dutch institutes for partially sighted and blind together 
with changed treatment criteria could be an additional explanation for the significantly 
higher number of infants with a visual acuity >0.3 found in the current study and the 
significant decrease in VI due to ROP. Although more infants received treatment in the 
current study, 33% (n=14) did not, of which 10 had a visual acuity of <0.3. Haines et al24 
also described that, even after implementation of screening guidelines, some children 
developed VI because of non-adherence to the screening protocol.
Studies from the UK on VI due to ROP as a proportion of childhood VI, covering the 
same period,4,25 show a tendency that compares favourably with our surveys. A study by 
Schiariti et al1 demonstrated an increase in ROP as well as severe ROP without changes 
in the incidence of VI when comparing neonates born in 1992-1996 and 1997-2001. 
Slidsborg et al5 found a more than twofold increase in the incidence of treated ROP cases 
born in Denmark from 2001 to 2005 compared with 1996-2000. This increase was most 
pronounced for the smallest infants. The number of infants with VI or blindness caused 
by ROP was stable. These studies also attribute the decline of VI due to ROP to a more 
complete ophthalmic surveillance, earlier treatment and improvement in neonatal care.
Similarly to the earlier Dutch surveys, most children with VI caused by ROP were surviv-
ing preterm neonates <30 weeks of gestation. This group of infants also showed the 
highest incidence of concomitant disabilities. Although a substantial number of infants 
had one or more concomitant disabilities (73.8%), no significant changes were found 
compared with the study of Termote et al. Inexplicably, no children with epilepsy were 
registered in the present study. The incidence of BPD, developmental delay and hearing 
deficit gradually increased whereas behavioural abnormalities, multiple disabilities and 
neurological impairment decreased minimally. A Dutch study by van Baar et al26 showed 
a clear association between preterm birth and multiple disabilities at 5.5 years of age in 
157 children born before 30 weeks GA. One or more disabilities were found in 75% of 
the children. Several other studies have concluded that the survival rate for extremely 
preterm born infants has improved over the past decade, but that the overall prevalence 
of neurodisability after preterm birth has not fallen, thus supporting the findings in our 
study.8-10 This overview of more than 30 years shows a decrease in GA and BW and a 
gradual increase in AV and supplemental oxygen administration, with a turning point 
in the early 1990s when novel treatments such as surfactant treatment, high frequency 
oscillation (HFO), postnatal steroids and inhaled NO were introduced. The incidence of VI 
caused by ROP has decreased over the past 30 years with the most obvious change seen 
in the last survey period. Additional changes in neonatal care practices such as treat-
ment with antenatal steroids and antenatal antibiotics together with earlier treatment 
for ROP could be an explanation. However, these changes did not result in a decrease of 
concomitant as well as multiple disabilities. Although more children were treated, 33% 
were not treated.
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Therefore, it can not be emphasised enough that timely screening, follow-up and treat-
ment, as well as close collaboration by all professionals involved in the care of these 
at-risk neonates should be our aim to enable a further decrease the number of children 
with VI caused by ROP. While the GA and BW of survivors continue to decrease, it seems 
a more difficult task to diminish the number of children with multiple disabilities.
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Provide insight in natural history, screening and treatment policy of Retinopathy of 
Prematurity (ROP) in the Netherlands.
Methods
A multicenter, prospective, population based study (NEDROP) included all preterm 
infants born in 2009 in the Netherlands fulfilling the inclusion criteria for ROP-screening. 
Anonymized data from ophthalmologists, neonatologists and pediatricians were 
merged on identification number.
Results
Of 2033 reported infants, 1688 (83%) were screened for ROP. ROP stage was reported 
in 100%, zone in 94.4% and plus disease in 83%. ROP developed in 324 (19.2%), mild 
ROP (stage 1-2) in 294 (17.4%), severe ROP (stage 3 or more) in 30 (1.8%) and 17 (1%) 
were treated. The initial screening examination was not performed within the required 
42 days in 641 (38%). Date for follow up was recorded 1973 times and accomplished 
within 3 days from the planned date in 1957 (99.2%). The chance of not being screened 
increased from 12.9% without transfer to another hospital to 23.5, 18.5 and 25% after 
respectively 1, 2 or 3 transfers.
Conclusion
The incidence of severe ROP and infants treated was low. NEDROP emphasizes that tim-
ing of initial examination and transfer to another hospital are issues of concern within 
the screening process.
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INTRODUCTION
Retinopathy of prematurity (ROP) is a vision threatening disease in prematurely born 
infants. Over the years, our knowledge about the disease has improved and its manage-
ment is evolving. At the same time, advances in neonatal care result in survival of an 
increasing number of infants with an extremely low gestational age (GA) which are the 
most susceptible to develop severe ROP.1 Careful screening and timely treatment play a 
key role in the reduction of the number of infants left with a permanent visual disability.
Several countries have developed evidence-based guidelines for screening and 
treatment of ROP.2–6 The last ROP guideline in the Netherlands, based on a national 
retrospective study by Schalij–Delfos et al7, is dated from 1997. Additionally, the In-
ternational Classification for ROP (ICROP) was revised in 2005, and the Early Treatment 
for ROP (ETROP) study changed the treatment algorithm.8,9 Therefore, revision of the 
Dutch guideline was imperative. A 30-year overview on visual impairment due to ROP 
in the Netherlands showed an increased risk of ROP among infants with decreasing GA 
and birth weight (BW), a relative reduction of visual impairment due to ROP but also an 
indication that not all infants at risk might have been seen or treated in time.10 So, before 
releasing a new ROP guideline, the necessity for insight in incidence and risk factors for 
ROP, adherence to the screening protocol and treatment policy in our country, called for 
a nationwide inventory on ROP: the NEDROP study.
METHODS
The NEDROP study is a multicentre, prospective, population-based study, and includes 
all preterm infants born in 2009 in the Netherlands that fulfilled the inclusion criteria for 
ROP-screening according to the prevailing guideline: GA <32 weeks and/or BW <1500 
g, and preterm infants that needed ≥40% supplemental oxygen for more than 3 days. 
Neonatologists and paediatricians provided coded information on all those who were 
eligible to enrol in the study: initials (first letter of first name and surname), zip code, 
date of birth, GA and BW. Multiple births were numbered consecutively (1/2, 2/2, 1/3, 
etc). Ophthalmologists reported the same coded information of all infants that were 
actually screened for ROP. On a specially designed form, they reported the date of first 
examination, the suggested and executed dates of follow-up examinations, the date 
and reason for discontinuation of screening, ROP classification, presence or absence 
of plus disease and need for treatment. According to the prevailing guideline, the first 
screening examination should be scheduled at 5 weeks (before 42 days) postnatal age 
(PNA). For study purposes, infants were categorised as mild (ROP stages 1 and 2) or 
severe (ROP stage ≥3) ROP. However, some data will be presented by stage of ROP. In 
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retrospect, infants were classified in Type 1 and Type 2 ROP, according to the ETROP 
criteria. At transfer, the next hospital’s name was noted. Data input for the NEDROP 
database was centralised and handled by one investigator (AvS).
Statistical analysis
Data files on patient characteristics and screening were merged on identification num-
ber. Numerical values are presented as medians with 25–75% IQR in brackets. Data about 
screening examinations and transfers are presented with minimum-maximum range. 
Data management and statistical calculations were done with the SAS V.9.2 package 
(SAS Institute, Cary, North Carolina, USA).
RESULTS
Population
All 103 hospitals involved in ROP screening (10 neonatal intensive care units (NICU), 
16 high-care centres (HC) and 77 regional centres (RC)) participated in the study. Neo-
natologists and paediatricians reported 2033 infants eligible for screening of which 
556	were	part	of	twins	or	triplets.	Infants	were	born	at	a	NICU	(1735;	85.3%),	a	HC	(177;	
8.7%)	or	 a	RC	 (121;	 6%).	Of	 the	 reported	 infants,	 1688	 (83%)	were	 screened	 for	ROP	
(figure 1). Their median BW and GA are presented in table 1. Of the reported infants, 
164 died, of which four were fully screened and, therefore, included in the study. For 
several other reasons, infants were not screened or lost to follow-up: the ophthalmolo- 
 Figure 1 Flowchart
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gist was not summoned (126), different inclusion criteria for screening were used (23), 
transfer of the infant to another hospital before the first screening (12), no show at the 
outpatient appointment (10), and transfer abroad (4). For 10 infants, the reason was 
unknown. Due to the anonymous data retrieval, it is not known if those not screened 
developed ROP.
ROP
Of the 1688 infants screened, 324 (19.2%) developed ROP, of which 294 were mild and 30 
severe (tables 1 and 2). The absolute numbers of infants with ROP increase with decreas-
ing GA (figure 2). At time of detection, ROP was located in Zone I in 7, Zone II in 133 
and Zone III in 166 cases. The zone was not noted in 18 (5.6%) infants. Plus disease was 
present in 32, absent in 237 and not noted in 55 (17%) infants. Treatment was performed 
in 17/324 infants with ROP (5.2%): three with ROP stage 2, 12 with ROP stage 3 and 2 
with ROP stage 4.
In retrospect, infants were divided in Type 1 and Type 2 ROP, according to ETROP criteria: 
of the 324 infants 21 could be classified as Type 1 ROP, 10 as Type 2 ROP, 280 did not fit 
the criteria, and 13 could not be categorized due to incompleteness of data. Of the 21 
infants with Type 1 ROP, 11 were treated (9× ROP 3, 2× ROP 2) and 10 regressed sponta-
Table 1 Study population characteristics
Screened for ROP No ROP Overall ROP Mild ROP Severe ROP




















































1st exam >42 days (N) 592 513 79 74 5
















Number (N) of infants, screening examinations and initial examinations > 42 days after birth.
Median values with 25-75 IQR for gestational age (GA), birth weight (BW), number of examinations, 1st 
screening examination and first detection of ROP.
PMA = postmenstrual age, PNA = post natal age, NA = not applicable, exam = examination
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neously. Six treated infants could not be categorized, two with stage 4 and four because 
notification of zone or plus disease lacked.
Screening
Ophthalmologists performed 3891 funduscopies. Infants that developed ROP were 
screened 1489 times, those without ROP2402 times. Roughly, the number of screening 
examinations increased with severity of disease (tables 1 and 2). Of the screened infants 
Table 2 Characteristics of infants with ROP specified per stage































Median gestational age (GA), birth weight (BW) and number of screening examinations with minimum-
maximum range in brackets. 
 
Figure 2 Number of infants with retinopathy of prematurity (ROP) and their distribution of gestational age 
(GA)
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544 (32.2%) had a BW ≥1500 g and 252 (14.9%) a GA ≥32 weeks. Data about initial screen-
ing and detection of ROP are displayed in table1. The initial screening was performed at 
a median age of 39 (11–334) days. At the first examination, 1480 had no ROP, 202 mild 
and six severe ROP. In 641 (38%) infants, the first screening examination was performed 
>42 days after birth. Three of these infants already had mild and five severe ROP. The 
date for follow-up screening was recorded 1973 times and accomplished within 3 days 
from the planned date in 1957 (99.2%). For five infants, the follow-up examination was 
outside this interval (range 1–8 weeks) without consequences for the outcome.
Transfer
More than half the population (59.6%) was born and cared for in the hospital of birth. 
The others were transferred once or more times, with a maximum of six (figure 3) times. 
Infants that had more than three transfers had been moved to and from a treatment 
centre. Of the non-transferred infants, 12.9% (156/ 1211), and of the infants with one or 
more transfers, 23% (189/822) had not been screened (p<0.001). However, no significant 
relation was found between the number of infants that were not screened, and the 
absolute number of transfers (p=0.64). 
 
Figure 3 Number of transfers and percentage screened. Number of transfers and percentage of screened / 
not screened infants are presented in the graph. Absolute numbers are presented in the adjoining table.
DISCUSSION
This prospective, population-based study was conducted with participation of all centres 
involved in ROP screening, thus providing insight in natural history, screening and treat-
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ment policy adherence in the Netherlands. This resulted in a large cohort of 2033 infants. 
The number of infants screened was high (83%) and comparable with a large cohort 
(n=13 282) described by Bain et al11 who found an overall rate of missed ROP screen-
ing of 18.6% in 2005 and 12.8% in 2007. Comparison of results on incidence of ROP is 
complicated as most studies are retrospective and not nationwide, and inclusion criteria 
vary. There are a number of studies with inclusion criteria similar to ours. Hoogerwerf 
et al12 studied a cohort retrospectively in the central part of the Netherlands, from 2001 
to 2005. They found similar incidences for overall ROP (23.3%) and severe ROP (1.2%). Ho 
et al13 found an incidence of 19.2% ROP (36/187), 9.6% severe ROP and 8.6% treatment in 
a retrospective study from 1996 to 2003 in a tertiary centre in the South Glasgow region. 
Larsson et al5 performed a population-based study in Stockholm County, Sweden, from 
1 August 1998 to 31 July 2000, and found ROP in 25.5% (100/392), severe ROP in 12.2% 
and treatment of 8.1%. Isaza et al14 reported ROP in 40.4% (171/423), severe ROP in 9.2% 
and treatment in 5.7% in a retrospective study in a NICU in Canada from July 2006 to July 
2010. A prospective study by Dhaliwal et al15 performed in Lothian, Scotland, from 1990 
to 2004 found ROP in 17%, severe ROP in 8.5% and 5% treatment in 474 infants born 
during 2000–2004.
The incidence of ROP in the current study (19.2%) is similar to most studies, but low for 
infants with severe ROP and those treated. The NEDROP population is large, covers the 
whole nation and includes all infants screened for ROP in 2009, also those ≥32 weeks 
and ≥1500 g (7.5%). This is reflected in a mean GA (30 weeks) and BW (1435 g) that is 
relatively high compared to the other studies, not including infants >32 weeks gesta-
tion. Only Isaza14 also included those judged at risk.
Furthermore, only one NEDROP infant had a GA <24 weeks, probably due to the contem-
porary Dutch policy not to resuscitate infants at birth with a GA <24 weeks.
We found a low number of treated infants. Retrospectively, 21 infants were classified 
with Type I ROP of which 11 were actually treated. If all Type 1 ROP infants would have 
been treated (27/1688=1.6%), the difference with the studies above would still be sub-
stantial. In 17%, plus disease was not recorded. It is unknown if plus disease was not 
recorded because it was absent or whether the implication of plus disease was not ap-
preciated by the ophthalmologist. An inventory on visual impairment due to ROP by van 
Sorge indicated that not all infants with severe ROP might have been treated in time.10 
This inventory again suggests that ETROP treatment criteria were not implied at large in 
2009, and not all infants are treated in time. The old guideline did not include a section 
about treatment supporting the necessity for guidelines to include rules for screening 
and also for treatment. This has been effected in the new national ROP guideline.
This study provides useful information about the screening process. The main devia-
tion of the protocol was a delay in the initial screening examination. According to the 
prevailing guideline, the first screening examination should take place at PNA 5 weeks 
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(<42 days). The median PNA at initial screening was 5.6 weeks. Figures about postmen-
strual age (PMA) (median 35.4 weeks) are not well comparable with others due to the 
substantial number of infants with GA >32 weeks in this study. For unknown reasons, 
641/1688 infants were screened >42 days of age. Eight of these infants already had ROP 
at the initial examination, of which five were severe. In a population-based study on 
severe ROP, Haines et al16 also found that 31/221 (14%) infants already had severe ROP at 
first screening in contrast with 0.4% in our study. Gupta et al,17 investigating 23 Canadian 
centers, found that eight different criteria were in use for timing of screening, and only 
40% initiated screening at 4–6 weeks.
PMA and PNA for the development of ROP and severe ROP was similar to other stud-
ies.18,19 A date for follow-up was recorded 1973 times and executed within 3 days of the 
intended date in 99%. This suggests that written recommendations increase the rate for 
follow-up.
Transfer has been reported as an important weak link in the screening process.20 Reyn-
olds et al21 described 13 ROP malpractice cases of which eight were related to failure 
to refer or follow-up. Attar et al20 found that the risk of not being screened at all was 
associated with transfer or discharge of the NICU before the initial eye examination, no 
written recommendation in the discharge summary, and no scheduled appointment at 
discharge to home.22 We anticipated that transfer could be a bottle neck in our screening 
process as policy of transfer changed. In the past, at least the initial screening examina-
tion was performed in a NICU resulting in a careful selection of high-risk infants whose 
transfer was postponed. Currently, infants are transferred to a HC or RC as soon as they are 
respiratory and circulatory stable, often before the first screening examination. As lack 
of screening or delay in follow-up can have devastating consequences, we should direct 
our efforts towards optimisation of communication and distribution of information. A 
recent study by Barry et al23 showed that the attendance rates for initial outpatient ex-
aminations and fulfilment of the screening programme significantly increased after they 
introduced parent education forms, streamlined scheduling and introduced a log book 
for follow-up monitored by the attending ophthalmologist. As a result of the NEDROP 
study, several indicators were added to our National Monitoring System for Quality 
in Health Care to improve the screening process. Shortly after births, parents should 
receive a ROP brochure, and the week for initial screening is defined and noted in the 
patient’s medical record. The neonatologist is obliged to include information about ROP 
screening in the letter of transfer (including ophthalmological data and a week number 
for first or planned follow-up screening), or infants get a scheduled appointment before 
discharge to home. Although the anonimysed data admission facilitated participation 
of all centers involved, it was also a limitation as neonatal and ophthalmological data 
were available for each individual patient, but could not be linked directly to the centre 
of care. For example, for individual infants, we do not know the reason they were not 
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screened, or the reason for discontinuation of screening after transfer. Furthermore, this 
study covered only 1 year of screening. There is, however, no reason to assume that this 
year would deviate much from other years. Finally, we should consider variability in the 
judgment of different examiners for staging and treatment of ROP. As the group is large, 
this observer bias is expected to level out in the final results.
Gilbert et al24 emphasized that each country should adjust its screening guidelines 
based on characteristics from its own population. The shortcomings in the execution 
of the 1997 guideline emphasize the need for evaluation of the implementation of 
guidelines even in well-structured healthcare systems. Ideally, this should be done 
in an obligatory national registry but the complexity to organize this as well as local 
privacy and legal regulations might prevent countries from institutionalizing such a 
register. The alternative is a national inventory on a regular basis. The NEDROP study 
resulted in a new guideline25 for screening and treatment of ROP. Oral communication 
at regional and national meetings, quality indicators and an online e-learning should 
second all-encompassing implementation, the results of which will be evaluated in the 
next national inventory.
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To study the incidence and risk factors for retinopathy of prematurity (ROP) in the Neth-
erlands.
Study design
Prospective, approximating population-based study that included infants with gesta-
tional age (GA) <32 weeks and/or birth weight (BW) <1500 g born in 2009. Pediatricians 
and ophthalmologists of all hospitals involved in care for premature infants reported 
data that were matched with the national perinatal database for risk factor analysis.
Results
Of 1380 infants, median GA 29.8 weeks (IQR 28.1-31.1) and median BW 1260 g (IQR 1020-
1500), ROP developed in 21.9%. Logistic regression identified GA and BW as risk factors 
for ROP (P < .001). After adjustment for GA and BW, additional risk factors were inhaled 
nitric	oxide	(iNO;	OR	2.6,	95%	CI	1.1-6.2,	P	=	.03),	stay	at	a	neonatal	intensive	care	unit	
>28 days (OR 1.6, 95% CI 1.1-2.6, P = .03), and artificial ventilation >7 days (OR 1.6, 95% 
CI 1.1-2.5, P = .02). Prenatal glucocorticoids (OR 0.6, 95% CI 0.4-0.8, P < .001) and female 
sex (OR 0.7, 95% CI 0.5-0.99, P = .04) showed a lesser incidence of ROP. iNO remained 
significant after correction for all significant factors (OR 2.6, 95% CI 1.1-6.2, P = .03).
Conclusion
In addition to established risk factors (GA, BW, stay at a neonatal intensive care unit >28 
days, and artificial ventilation >7 days), treatment with iNO as risk factor for ROP is a 
novel finding.
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INTRODUCTION
Retinopathy of prematurity (ROP) accounts for 5.5%-20% of childhood blindness in 
developed countries.1 Improvement in neonatal care during the past 2 decades has 
increased the survival of prematurely born infants and lowered the gestational age (GA) 
and birth weight (BW) of survivors.2 Several studies demonstrated that this decrease in 
mortality was accompanied by an increase in significant neonatal morbidities such as 
severe ROP.3,4 ROP is a condition confined to the developing retinal vasculature in the 
prematurely born infant and develops in 2 phases. Vascularization of the retina begins 
at 16 weeks’ and reaches the peripheral retina at 40 weeks’ gestation. When infants are 
born prematurely, the growth of vessels ceases, leaving an incompletely vascularized pe-
ripheral retina. Insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor 
(VEGF) are crucial to the normal development of retinal vessels. IGF-1 is produced by 
the placenta, and preterm birth results in decreased levels of serum IGF-1. Very prema-
turely born infants cannot produce sufficient IGF-1, and its concentration may be further 
reduced by sepsis, acidosis, and poor nutrition, which are frequent conditions in those 
infants. These low levels of IGF-1 are coresponsible for the cessation of retinal vessel out-
growth. The expression of VEGF is regulated by oxygen. ROP can be initiated immediately 
after premature birth by relative hyperoxia, as supplemental oxygen but also room air 
increases retinal oxygen saturation to levels far greater than those in utero. Most preterm 
infants do not get ROP, but in those who do, this hyperoxia suppresses the production 
of VEGF, resulting in a hypoxic, avascular retina. Subsequently, chronic hypoxia leads to 
compensatory, excessive VEGF synthesis, causing pathologic neovascularization.5,6
Because oxygen and the extent of the avascular peripheral retina play a key role in the 
pathogenesis of ROP, factors influencing oxygen levels as well as factors responsible 
for large areas of avascularity are expected to be associated with an adverse outcome. 
Low GA, low BW, and factors related to general illness such as length of stay (LOS) on a 
neonatal intensive care unit (NICU), duration of artificial ventilation, and the administra-
tion of supplemental oxygen are established risk factors.7
Screening and treatment protocols vary by country and may result in differences in 
incidence and risk factors for ROP. To provide optimal care for premature infants at risk, 
a nationwide inventory was conducted to provide up-to-date insight on the incidence 
and potential risk factors for ROP in the Netherlands.
METHODS
The Netherlands ROP (NEDROP) study is a multicenter, prospective, approximating 
population-based study in which investigators analyzed all infants born in 2009 eligible 
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for screening of ROP according to the prevailing guideline: GA <32 weeks or BW <1500 
g or preterm birth and treatment with >40% supplemental oxygen for more than 3 
days. Pediatricians and ophthalmologists of the 103 Dutch hospitals involved in care 
for premature infants reported all infants entitled for ROP screening to the study center. 
Ophthalmologists reported all infants actually screened for ROP as well as ROP clas-
sification, the presence of “plus disease” (additional signs of active disease), screening 
schedule, and whether there was need for treatment. ROP was classified according to 
the International Classification of ROP, the highest stage in either eye being reported.8 
Data entry in the NEDROP database was coordinated, centralized, and handled by one 
investigator (A.v.S.). To comply with patient privacy regulations, infants were reported 
anonymously with initials, zip code, date of birth (DOB), GA, and BW. The NEDROP 
database was merged with the already-existing Netherlands Perinatal Registry, which 
is a medical, professional-based registry where pediatricians and neonatologists report 
their data of neonates born in the Netherlands. Contribution to the Netherlands Peri-
natal Registry is obligatory for NICUs and high-care centers and voluntary for regional 
centers of which 50% participate.
All infants born with a GA <30 weeks and 85%-90% of infants with GA 30-32 weeks are 
admitted to a NICU. Yearly, more than 95% of infants born <32 weeks’ gestation are 
reported to the Netherlands Perinatal Registry.
To combine the NEDROP and the Netherlands Perinatal Registry databases, DOB and/or 
zip code and/or BW were applicable. Clinical data were classified according to the defini-
tions	of	the	Netherlands	Perinatal	Registry;	for	bronchopulmonary	dysplasia	(BPD),	the	
new definition was used (need of supplemental oxygen at 36 weeks’ postmenstrual 
age);	 artificial	 ventilation	 meant	 ventilation	 via	 an	 endotracheal	 tube	 (synchronized	
intermittent mandatory ventilation or high-frequency ventilation). Longer stay at a NICU 
and duration of artificial ventilation were regarded as indicators for severe illness and 
defined as stay at a NICU for more than 28 days and artificial ventilation more than 7 days 
(http://www.perinatreg.nl/wat_wordt_geregistreerd). All neonatologists provided their 
2009 inhaled nitric oxide (iNO) protocol. No interventions in practice and screening, to 
reduce the rate of ROP, were undertaken throughout the study. The study was approved 
by the Institutional Review Board (Medical Ethical Committee of Leiden University Medi-
cal Center, the Netherlands).
Statistical Analyses
GA and BW are presented as median values with the IQR (25th-75th percentile). The 
occurrence of risk factors in the study population and the incidence of ROP were tabu-
lated as numbers and percentages. Some of the characteristics such as sex, small for 
gestational age, duration of artificial ventilation, duration of O2, and LOS on NICU were 
not filled out for every patient in the Netherlands Perinatal Registry.
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We handled them as missing data. A logistic regression model was used to investigate 
the association between a risk factor and the development of ROP, corrected for possible 
confounders. Because part of the data consisted of observations on multiple births, risk 
factors and probability of ROP for these neonates were correlated. To take into account 
this dependency of the data, a generalized estimating equation approach was used to 
estimate	the	coefficients	of	the	logistic	regression	model	(proc	GENMOD	in	SAS;	SAS	Insti-
tute, Cary, North Carolina). For each potential risk factor, the OR and the 95% CI, adjusted 
for GA and BW, were calculated. The final adjusted OR was obtained from the model that 
included all the significant factors. P < .05 was considered statistically significant.
RESULTS
In the NEDROP database, 1900 infants with GA <32 weeks and/or BW <1500 g were 
reported, of which 1561 (82.2%) were screened for ROP. The NEDROP and the Neth-
erlands Perinatal Registry database were merged by DOB and zip code, resulting in a 
 
 
Live borns in 2009: N = 184.915 
Eligible for ROP-screening: N = 2193 
 
164 died (4 screening completed) 





GA < 32 weeks or BW < 1500 gr 
and screened for ROP: 
 
N = 1561 
Study population: 
GA < 32 weeks or BW < 1500 g, 
screened and coupled to PRN 
 
N = 1380 
Mild ROP : N = 273   Severe ROP : N= 29 
 
GA < 32 weeks or BW < 1500 gr: 
 
N=1900 
Figure 1 Flowchart of the study.
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complete set of combined perinatal and ophthalmologic data of 1380 of 1561 infants 
(88%). A detailed flow chart of the study population is presented in Figure 1, and clinical 
characteristics are shown in Table 1. All ophthalmologists involved in ROP screening 
participated in the NEDROP study.
The	 incidence	 of	 ROP	 in	 the	 study	 population	 was	 302	 of	 1380	 (21.9%);	 273	 infants	
(19.8%) developed mild ROP (stage 1 and 2) and 29 infants (2.1%) severe ROP (>stage 
3). The infants had a median GA 29.8 (IQR 28.1-31.1) weeks and median BW 1260 (1020- 
Table 1 Descriptive statistics
N ROP %
N 1380 302 (21.9)
Characteristic N (%) characteristic + characteristic −
Female gender 527 (44.7) 20.5 21.7
Extremely low BW (<1000g) 323 (23.4) 51.1 13.0
Small for GA (<P10) 106 (9.0) 23.6 25.9
Multiple birth 404 (29.4) 19.3 23.0
Duration of AV yes, ≤7 days 360 (30.5) 21.4
yes, >7 days 169 (14.3) 53.3
No 650 (55.1) 12.6
Duration of O2 yes, ≤28 days 484 (44.9) 16.3
yes, >28 days 210 (19.5) 50.9
No 383 (35.6) 13.8
LOS NICU yes, ≤28 days 789 (67.1) 12.2
yes, >28 days 259 (22.0) 51.0
No 128 (10.9) 14.1
BPD 65 (4.7) 58.5 20.1
Patent ductus arteriosus 235 (17.0) 40.9 18.0
Sepsis 404 29.3) 31.7 17.8
IVH / PVH 207 (15.0) 30.9 12.2
iNO 23 (1.7) 47.8 21.4
Prenatal glucocorticoïds 622 (45.1) 19.6 23.7
Postnatal glucocorticoïds 78 (5.7) 57.7 19.7
IRDS 663 (48.0) 26.7 17.4
NEC with perforation 27 (2.0) 63.0 21.1
Hyperglycaemia (>8mmol/l) 139 (10.1) 45.3 19.3
Packed cells 549 (39.8) 33.9 14.0
ELBW,	extremely	low	birth	weight;	IVH/PVH,	intra-	periventricular	hemorrhage;	NEC,	necrotizing
enterocolitis;	RDS,	respiratory	distress	syndrome;	SGA,	small	for	GA.
The denominator is 1380 except for some characteristics with missing data: female sex
(n = 1180), small for GA (n = 1176), multiple birth (n = 1372), duration of artificial ventilation
(n = 1179), duration of supplemental O2 (n = 1077), and LOS at NICU (n = 1176).
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1500) g, those with ROP 28.0 (26.4-29.4) weeks and 950 (780-1212) g and with severe 
ROP 26.3 (25.4-27.0) weeks and 890 (730-1060) g. Logistic regression analysis identified 
GA and BW as significant risk factors for ROP (P < .0001).
After adjustment for GA and BW, additional risk factors were as follows: iNO (OR 2.6, 
95% CI 1.1-6.2, P = .03), NICU stay >28 days (OR 1.6, 95% CI 1.1-2.6, P = .03), and artificial 
ventilation >7 days (OR 1.6, 95% CI 1.1-2.5, P = .02). Prenatal glucocorticoids (OR 0.6, 
95% CI 0.4-0.8, P < .001) and female sex (OR 0.7, 95% CI 0.5-0.99, P = .04) showed a 
significantly lower incidence of ROP (Table 2).
Twenty-three infants were treated with iNO. Of these, 47.8% developed ROP and 8.7% 
severe ROP. In 2009 iNO was administered in the first weeks of life in dosages of 5-20 
parts per million (ppm), the vast majority of the hospitals starting with 20 ppm. Because 
of the potential confounding effect of other risk factors on the association of iNO and 
ROP, a final adjusted OR for iNO was estimated from the model that included all factors 
found to be significant in this study. iNO continued to be a significant risk factor for 
Table 2 Risk factors associated with the development of ROP corrected for GA and BW.
OR p-value 95% CI
Obstetric characteristics and interventions
Prenatal glucocorticoids 0.6 0.0002 0.4-0.8
Multiple birth 1.1 0.59 0.8-1.6
Infant characteristics
Female Gender 0.7 0.04 0.5-1.0
Neonatal morbidity
Sepsis 1.3 0.13 0.9-1.7
IVH / PVH 1.0 0.90 0.7-1.5
PVL 1.0 0.99 0.3-3.0
Patent ductus arteriosus 1.0 0.99 0.7-1.4
IRDS 1.1 0.66 0.8-1.4
BPD 1.3 0.35 0.7-2.3
NEC with perforation 2.3 0.09 0.9-5.9
Hyperglycaemia (>8 mmol/l) 1.2 0.53 0.7-1.8
Neonatal interventions
Packed cells 1.1 0.50 0.8-1.5
iNO 2.6 0.03 1.1-6.2
Postnatal glucocorticoïds 1.6 0.08 0.9-2.8
NICU admission (weeks) 1.2 0.0002 1.1-1.2
AV (weeks) 1.2 0.0016 1.1-1.4
Oxygen administration (weeks) 1.1 0.08 1.0-1.1
IRDS,	infant	respiratory	distress	syndrome;	PVL,	periventricular	leukomalacia.
Significant risk factors are in italic.
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ROP (OR 2.6, 95% CI 1.1-6.2, P = .03). Because of the small number of infants treated the 
confidence interval is wide.
DISCUSSION
This nationwide inventory of infants born in 2009 in the Netherlands yielded a very large 
database because of the participation of all Dutch pediatricians, neonatologists, and 
ophthalmologists from hospitals involved in care for premature infants. Treatment with 
iNO for hypoxic pulmonary failure was found to be a risk factor for the development 
of ROP. Other already-known risk factors confirmed by this study were GA, BW, LOS in 
the NICU, and duration of artificial ventilation. A cohort study of Hoogerwerf et al3 per-
formed in the central Netherlands during 2001-2005 supported the results of this study. 
Comparable incidences of overall ROP (23.3% vs 21.9%), mild ROP (22.2% vs 19.8%), 
and severe ROP (1.2 vs 2.1%) were found and duration of artificial ventilation was found 
to be a significant risk factor for ROP. This study did not include data on iNO. Prenatal 
glucocorticoids and female sex were, as reported in other studies, related with a lower 
incidence of ROP.9,10 Seiberth and inderkamp11 demonstrated artificial ventilation for >7 
days to be a risk factor for ROP. Amultivariate logistic regression analysis in a Chinese 
cohort study by Huang et al12 showed that low BW and mechanical ventilation were 
significantly associated with ROP. Furthermore, Martinez-Cruz et al13 performed a pro-
spective study in their National Institute of Perinatology in Mexico and found several risk 
factors associated with the development of ROP, among which were GA, LOS on a NICU, 
mechanical ventilation, and oxygen therapy. The beneficial role of antenatal glucocorti-
coids on the severity of ROP is described by Higgins et al.9 Given before birth, maturation 
of the fetal lung is stimulated, resulting in a reduction in respiratory distress syndrome, 
associated with decreased morbidity and mortality.14,15 Darlow et al10 identified male sex 
as a risk factor for ROP. Binet et al16 found no difference in the rates of ROP between the 
two sexes, but male infants were more likely to die or have an adverse neonatal outcome 
than female infants and have poorer respiratory outcomes. The authors hypothesized 
that antenatal corticosteroids do not benefit male infants as much as they do premature 
female infants. Several studies describe an advantage in the survival of girls among 
premature infants supposedly related to differences in hormonal milieu and severity of 
illness.17,18 The fact that administration of antenatal glucocorticoids and female sex both 
reduce morbidity can be an explanation for the reduced risk of ROP. iNO was found to 
be a risk factor for ROP. iNO may help to reduce hypoxic respiratory failure in preterm 
infants. It vasodilates the pulmonary vasculature through relaxation of smooth muscle 
cells, thereby improving oxygenation. Models in animals indicate that hyperoxia affects 
microvascular development in the lung and reduces the expression of VEGF. Currently 
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iNO is the treatment of choice for term infants with persistent pulmonary hypertension 
who do not respond to mechanical ventilation with high fractions of inspired oxygen 
and treatment with vasopressor-drug therapy.
In preterm infants, the use of iNO is a relatively new treatment modality.19 It has been 
given as rescue therapy for severe acute respiratory failure, as prophylaxis to prevent 
BPD, and as treatment for severe BPD.20 The influence of iNO on survival, chronic lung 
disease (CLD), and adverse neurologic events has been evaluated in a Cochrane system-
atic review and more recently in a systematic review by Donohue et al.20,21 These reviews 
included 14 randomized controlled trials of iNO therapy in preterm infants and reported 
a reduction of 7% in the combined outcome of death or CLD. No evidence was found that 
iNO influenced the rate of other complications of prematurity such as severe ROP. Askie et 
al22 performed an individual-patient data analysis in which raw data from 3298 individual 
participants of 12 randomized controlled trials were re-evaluated. There was no evidence 
that iNO therapy had a statistically significant effect on the primary end points of death, 
CLD, or severe neurologic sequelae. The use of a greater starting dose (>5 ppm) seemed 
to be associated with a better outcome, but the differences in the design of the included 
trials were substantial, making it difficult to draw strong conclusions.
In the current study, iNO treatment and development of ROP were found to be signifi-
cantly associated. A possible explanation for this discrepancy may be that, contrary to 
previous studies, iNO treatment in the Netherlands, at the time of the NEDROP study, was 
only used as rescue therapy for preterm infants with a very high oxygenation index and 
not routinely in preterminfants with pulmonary disease. It was administered in dosages 
5-20 ppm, the majority starting with 20 ppm, whereas other studies report maximum 
doses of 5-10 ppm and even treated infants routinely for pulmonary disease.22
There might be doubt whether iNO is correlated to supplemental oxygen use, artificial 
ventilation, or just following the severity of disease reflected in the time spent at a NICU.
However, in this study, iNO continued to be significant after correction for such variables.
It is postulated that VEGF is an important mediator in the development of ROP. The 
relationship between iNO and ROP may be explained by the acutely increased oxygen 
saturation after the initiation of iNO treatment. This hyperoxia is also present in the ret-
ina. High oxygen tensions damage immature retinal capillary endothelial cells, thereby 
preventing complete vascularization, and cause further downregulation of VEGF, which 
compromises outgrowth of retinal vessels, thus facilitating the vaso-obliterative first 
phase of ROP. Because of its rapid effects, iNO therapy is also associated with large 
fluctuations in arterial pO2, another known risk factor for ROP.23 These fluctuations may 
cause an imbalance of VEGF and therefore additionally enhance the negative effect on 
outgrowth of retinal vessels.
The strength of this national study is the extent and the completeness of the database, 
providing a realistic picture of the situation in our country. The anonymized data fa-
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cilitated participation of all centers involved in care for the prematurely born. On the 
other hand, this anonymized data retrieval is also one of the limitations of the study as 
neonatal and ophthalmologic data were available for each individual patient but could 
not be linked directly to the center of treatment. Although the data retrieved were 
extensive, they did not provide information specific enough to calculate the relation 
between severity of illness and iNO bymeans of the oxygenation index or the Clinical 
Risk Index for Babies score, both measures of general illness.24,25 For example, data per 
infant about start of treatment, doses administered, duration of treatment and targeted 
oxygen saturation during treatment with iNO are not available.
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To develop a new national screening guideline for retinopathy of prematurity (ROP).
Methods
Included were infants of the 2009 prospective ROP inventory in the Netherlands with 
gestational age (GA) <32 weeks and/or birth weight (BW) <1500 g. Five models were 
studied, based on GA and BW in combination with no, one or a set of five risk factors 
for ROP. Risk factors were determined by logisticregression. In MEDLINE and EMBASE, 
additional risk factors were searched. A precondition was that no infants with severe 
ROP would be missed. Receiver operating characteristic curves or classical measures 
were used to determine diagnostic accuracy.
Results
The model including all infants with severe ROP comprised screening of infants with 
GA <30 weeks and/or BW <1250 g and a selection of infants with GA 30–32 weeks and/
or BW 1250–1500 g, with at least one of the following risk factors: artificial ventilation 
(AV), sepsis, necrotising enterocolitis (NEC), postnatal glucocorticoids or cardiotonica. 
This model would not detect 4.8% (95% CI 2.5% to 8.0%) of infants with mild ROP and 
would reduce infants eligible for screening by 29%.
Conclusions
In the Netherlands, screening may be safely reduced using a new guideline based on GA, 
BW, AV, sepsis, NEC, postnatal glucocorticoids and cardiotonica.
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INTRODUCTION
Retinopathy of prematurity (ROP) is a serious vasoproliferative disease of the retina of 
the very premature infant, which may lead to visual impairment or blindness. Treatment 
is possible and laser therapy is still preferable. As treated eyes have a better visual out-
come than untreated eyes, timely detection of ROP through screening is important.1 Dif-
ferent screening criteria are used worldwide and depend mainly on national incidences 
of ROP, which in their turn mainly depend on socioeconomic factors and local neonatal 
care. However, highly developed countries vary in their criteria also. The current UK 
guideline recommends screening of all infants with a birth weight (BW) ≤1500 g or a 
gestational age (GA) ≤31 weeks.2 The American guideline advises screening all infants 
with a BW <1500 g or a GA ≤30 weeks and selected infants between 1500 g and 2000 
g with an unstable course.3 The screening criterion of Sweden is GA ≤31 weeks.4 The 
Dutch guideline dating from 1997 advises screening infants with a BW <1500 g and/or a 
GA <32 weeks or preterm infants treated ≥3 days with ≥40% oxygen.5 These guidelines 
have in common that they screen infants with GA ≤30 weeks, and most screen infants 
with GA 30–32 weeks. In the past decade, the incidence of ROP has altered. In Central 
Netherlands, a significant decrease in the incidence of overall and severe ROP was seen 
in infants with BW <1000 g in the period 2001–2005 compared with 1991–1995.6 Also, 
Tan et al7 found a reduction in the incidence of severe ROP in southeast Scotland from 
1990 to 2009.
As screening for ROP is uncomfortable for the neonate, and costly and time consuming 
for the ophthalmologist, the aim of this study was to evaluate whether our inclusion 
criteria for screening could be reduced on the condition that no infant with severe ROP 
would be missed.
METHODS
The study group consisted of patients included in the NEDROP study, a prospective 
inventory of ROP in preterm infants born in the Netherlands in 2009. Paediatricians and 
neonatologists of the 103 Dutch hospitals involved in the care of premature infants 
reported all infants eligible for ROP screening according to the national guideline to the 
study centre.5 Ophthalmologists reported all infants actually screened for ROP, any ROP 
classification, presence of ‘plus disease’, screening schedule and treatment. The NEDROP 
study was approved by the institutional review board (medical ethics committee of 
Leiden University Medical Centre, the Netherlands).
To extend the clinical data of the study infants, coupling to the national perinatal reg-
istry (PRN) was performed. This database contains data of more than 95% of all infants 
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with GA <32 weeks and/or BW <1500 g.8 Because of the lack of data for older and heavier 
infants, only infants with GA <32 weeks and/or BW <1500 g screened for ROP were in-
cluded. Infants were categorized into two groups: infants with GA <30 weeks and/or BW 
<1250 g (high risk (HR) group) and infants with GA 30–32 weeks and/or BW 1250–1500 
g who do not fit into the HR group (moderate risk (MR) group). Clinical data, such as 
infant respiratory distress syndrome (IRDS), bronchopulmonary dysplasia (BPD), sepsis, 
intra-/periventricular haemorrhage (IVH/PVH), necrotising enterocolitis (NEC) and pre- 
and postnatal glucocorticoids were classified according to the definitions of the PRN.8 In 
those cases where one or more characteristics were not recorded, we considered these 
data as missing. ROP was classified following the International Classification of ROP.9 
ROP was categorised as mild (stages 1–2) or severe (stages 3–5). A thorough search of 
the literature for risk factors of ROP was performed in MEDLINE and EMBASE from 2006 
to December 2011 using the search terms ROP, risk factor(s), prematurity, screening and 
guideline. Papers were limited to English, Dutch, French and German language. Refer-
ence lists of selected manuscripts were examined for additional relevant publications. 
Only those factors registered in our PRN, easily accessible and available at the time of 
the first screening were selected.
To improve the efficacy of our current screening programme, several models were stud-
ied and compared with regards to reduction in the number of infants to be screened and 
the number of infants with ROP that would not have been detected on the precondition 
that no infant with severe ROP would be missed. A second precondition was that the 
model should be easy to use clinically and would be implementable. First we investi-
gated if screening could be reduced to infants in the HR group (model 1). Secondly, a 
prediction model for all infants of the study group was developed, based on GA and BW 
model 2). Then one additional risk factor was added to the model based on GA and BW 
for all study group infants (model 3).
Risk factors investigated were pre- and postnatal glucocorticoids, length of stay (LOS) on 
a neonatal intensive care unit (NICU), duration of artificial ventilation (AV), inhaled nitric 
oxide (iNO), gender, sepsis, IVH/PVH and NEC. In model 4 we investigated combining 
screening of the HR group with infants in the MR group with one specific risk factor, 
apart from GA and BW. Therefore, for infants in the MR group, a model based on BW, GA 
and one additional risk factor was developed. Risk factors included were those of model 
2, as well as patent ductus arteriosus, IRDS, BPD, supplemental oxygen, cardiotonica 
and erythrocyte transfusions. In model 5, screening of the HR group was combined with 
screening of infants in the MR group with at least one risk factor of a selected set of risk 
factors, including AV, postnatal glucocorticoids, cardiotonica, sepsis and NEC.
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Statistical analysis
To calculate the probability that a child will develop mild or severe ROP based on GA 
or BW, a multinomial logistic regression model was applied. Additional risk factors for 
the development of ROP were explored with logistic regression. As some of the data 
consist of observations on multiple births, risk factors and probability of ROP for these 
neonates will be correlated. To take into account this dependency of the data, a gener-
alised estimating equation approach was used to estimate the coefficients of the logistic 
regression model.
For each risk factor, a logistic regression model, including GA and BW, was explored. 
The ability of the model to discriminate between no ROP and ROP was quantified by 
the area under the receiver operating characteristic curve (AUC). For a model to be clini-
cally useful, the predicted probabilities have to be low for children who do not develop 
ROP, intermediate for children with mild ROP and high for children with severe ROP. This 
was assessed graphically by plotting histograms of the predicted probabilities in the 
three groups.Classic measures for the diagnostic accuracy of model 1 and model 5 were 
calculated with 95% CIs.
RESULTS
Neonatologists and paediatricians reported 2193 infants, of whom 160 (7.3%) died be-
fore screening was completed. Of the remaining 2033 infants, 1688 (83%) were screened 
for ROP, of whom 1561 infants had GA <32 weeks and/or BW <1500 g.
After coupling to the PRN, 1380 infants were eligible to enter the study (81.8% of the 
screened population). Among these infants were 352 multiple births to 173 mothers. In-
fants had a median GA of 29.8 weeks and median BW was 1260 g. Clinical data are shown 
in table 1.	The	incidence	of	overall	ROP	was	21.9%	(302/1380);	the	incidence	of	mild	ROP	
was 19.8% (273/1380) and severe ROP, 2.1% (29/1380). A gradual decline in predicted 
probability for mild as well as severe ROP with increasing GA is seen in figure 1.
In the HR group (n=871), 246 infants (28.2%) developed mild and 28 infants (3.2%) severe 
ROP. If screening was confined to the HR group (model 1), a sensitivity of 0.91 (274/302) 
(95% CI 0.86 to 0.94), specificity of 0.45 (481/1078) (95% CI 0.41 to 0.48) and a reduction 
of infants to be screened of 36.9% (509/1380) was found. However, 10% (27/273) with 
mild and 3.4% (1/29) with severe ROP would have been missed.
In model 2, a prediction model for all infants of the study group was developed based 
on GA and BW. GA and BW were the most important risk factors for ROP in our study 
group	(GA,	p<0.0001;	BW,	p	<0.0001).	The	AUC	for	this	model	was	0.80.	Figure 2 shows 
the predicted probability of ROP using this model.
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For infants without ROP, prediction was good, as the predicted probability was ≤0.20 for 
71.7% of infants with no ROP. For patients with mild and severe ROP, prediction was less 
accurate. Only 36.2% of infants with mild ROP had a predicted probability between 0.35 
and 0.65, and only 24.1% of infants with severe ROP had a predictive probability ≥0.70.
In model 3, the following risk factors were added to GA and BW, one at a time: pre- and 
postnatal glucocorticoids, LOS on NICU, duration of AV, iNO, gender, sepsis, IVH/PVH and 
NEC. None of these risk factors resulted in improvement in AUC.
In the MR group (n=509), 27 infants (5.3%) developed mild and one infant (0.2%) severe 
ROP. The AUC of the model, based only on GA and BW, was moderate in the MR group 
(0.69). Addition of any of the following risk factors gave no improvement in AUC: pre- 
and postnatal glucocorticoids, gender, sepsis, IVH/PVH, patent ductus arteriosus, IRDS, 
Table 1 Clinical characteristics of the study group, and incidence of (severe) ROP for each Characteristic




N 1380 302 (21.9) 29 (2.1)
Median gestational age (wks) (P25-P75) 29.8 (28.1-31.1) 28.0 (26.4-29.4) 26.3 (25.4-27.0)
Median birth weight (g) (P25-P75) 1260 (1020-1500) 950 (780-1212) 890 (730-1060)
Extremely low Birth weight (<1000g) 345 (25.0) 178 (51.6) 6 (1.7)
Small for gestational age (<P10) 106 (7.7) 25 (23.6) 1 (0.9)
Female gender 527 (38.2) 108 (20.5) 13 (2.5)
AV 529 (38.3) 167 (31.6) 20 (3.8)
Supplemental O2 administration 694 (50.3) 186 (26.8) 22 (3.2)
NICU Admission 1048 (75.9) 228 (21.8) 21 (2.0)
BPD 65 (4.7) 38 (58.5) 8 (12.3)
Sepsis 404 (29.3) 128 (31.7) 15 (3.7)
IVH / PVH 207 (15.0) 64 (30.9) 8 (3.9)
iNO 23 (1.7) 11 (47.8) 2 (8.7)
Prenatal glucocorticoïds 622 (45.1) 122 (19.6) 11 (1.8)
Postnatal glucocorticoïds 78 (5.7) 45 (57.7) 14 (17.9)
IRDS 663 (48.0) 177 (26.7) 20 (3.0)
NEC with perforation 27 (2.0) 17 (63.0) 5 (18.5)
Erythrocyte transfusion 549 (39.8) 186 (33.9) 20 (3.6)
AV = artificial ventilation
NICU = neonatal intensice care unit
BPD = bronchopulmonary dysplasia (extra O2 need at 36 weeks of gestation)
IVH/PVH = intra-or periventricular haemorrhage
iNO = inhaled nitric oxide
IRDS = infant respiratory distress syndrome
NEC= necrotising enterocolitis
P= percentile
*percentages: fraction of patients in this group with ROP or severe ROP, unless indicated otherwise
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Figure 1 Predicted probability of no, mild and severe ROP in relation to gestational age for preterm infants 
born in 2009 in the Netherlands. 
 
Figure 2 Predicted probability of ROP based on GA and BW for infants in the study group classified by 
observed ROP.
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BPD, duration of AV, LOS on NICU, iNO, supplemental oxygen, cardiotonica, NEC and 
erythrocyte transfusion (range of AUCs 0.68–0.72) (model 4). For model 5, a set of risk 
factors was selected. Of the risk factors found through the literature search, AV, postnatal 
glucocorticoïds, cardiotonica, sepsis and NEC met our selection conditions.
Of the 509 infants in the MR group, 107 needed AV, four postnatal glucocorticoïds, 28 
had cardiotonica, 105 had sepsis and 10 had NEC. No risk factors were found in 271 
infants	(53.2%)	and	≥1	risk	factors	in	177	infants	(34.8%);	data	for	61	infants	(12.0%)	were	
incomplete. The true positive rate (TPR) of model 5 was 0.26 (289/1109) (95% CI 0.23 to 
0.29) and the true negative rate (TNR) was 0.95 (258/271) (95% CI 0.91 to 0.98), assuming 
that children with missing data were also screened. The TPR of this model was low but 
no infant with severe ROP, and only 13/273 infants with mild ROP, were missed. Introduc-
tion of model 5 would result in exclusion from screening of at least 19.6% (271/1380) 
of infants in the study group, again assuming that infants with missing data are also 
screened. In comparison with the old guideline, this model would have resulted in a 
reduction of 29.0% (452/1561) of infants and 21.2% (786/3705) of examinations (table 2).
DISCUSSION
The aim of this study was to develop a new guideline for ROP screening in the Nether-
lands, on condition that restriction of the inclusion criteria for screening would not lead 
to infants with severe ROP being missed. For development of the guideline, a predic-
tive ROP model was evolved for which ROP and clinical data for all infants with GA <32 
weeks and/or BW <1500 g born in the Netherlands in 2009 and completely screened for 
ROP were used. Five different models were investigated. The model which included all 
infants with GA <30 weeks and/or BW <1250 g as well as infants with GA 30–32 weeks 
and/or BW 1250–1500 g with one or more of the risk factors AV, NEC, sepsis, postnatal 
glucocorticoids or cardiotonica, predicted the risk of ROP best (TPR 0.26 and TNR 0.95). 
Table 2. Reduction in number of infants that need to be screened and in number of fundus examinations 










< 32 wks and/or < 1500g 1561 3705
< 32 wks and/or < 1500g
(study group coupled to PRN)
1380 3339 11.6 9.9
< 30 wks and/or < 1250g (HR Group) 871 2539 44.2 31.5
< 30 wks and/or < 1250g and
30-32 wks and/or 1251-1500g with ≥ 1 risk factor 
or unrecorded risk factors
1109 2919 29.0 21.2
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Using this model, no infant with severe ROP was missed and 4.8% with mild ROP were 
missed. We performed a literature search to find the most established risk factors for 
ROP and compared these with those available in our database and found in our study. 
Apart from being easily accessible, they should be available before the age of 5 weeks 
postpartum, as this is the time at which ROP screening for many infants already starts. 
Seiberth et al, Karna et al and Hoogerwerf et al demonstrated that duration of AV is a risk 
factor for (severe) ROP.6,10,11 Treatment with dopamine was a risk factor for (severe) ROP 
in studies of Mizoguchi et al and Liu et al.12,13 Hoogerwerf et al, Smolking et al and the 
systematic review of the Cochrane database showed that (late) treatment with postnatal 
steroids is a risk factor for ROP.6,14,15 Lee, Chen et al, Weintraub et al and Jensen et al 
demonstrated perinatal infection/inflammation or sepsis to be a risk factor for (severe) 
ROP.16–19 Arrøe proved this for NEC.20 Most national ROP guidelines are based on GA and/
or BW, the major risk factors for ROP. Another important risk factor, postnatal illness, 
is seldom considered. Recently, four ROP screening models based on postnatal course 
were developed: WINROP, ROPscore, cumulative illness severity and a model based on 
Clinical Risk Index for Babies score, multiple birth, race and gender.21–24 All predicted 
proliferative ROP requiring treatment appropriately.
The former mentioned models could not be applied to our study as the PRN contains 
only limited information. Due to privacy regulations, data were also not accessible. In 
order to reflect the postnatal course, we added the risk factors AV, cardiotonica, post-
natal steroids, sepsis and NEC, to GA and BW as selection criteria in our new screening 
guideline.
Our new guideline has two important advantages. First, compared with the old one, 
this model reduced the number of infants who required eye examinations by 29%, 
whereas 4.8% of infants with mild ROP and no infants with severe ROP would have gone 
undetected. This corresponds with a reduction of 21% of fundoscopies. As screening 
is stressful for the neonate, this decrease is important. On the other hand, we should 
also consider that screening can be made less uncomfortable for the infant and more 
efficient for the ophthalmologist by swaddling of the infant, use of a pacifier and/or 
sucrose, and by good positioning of the infant. Secondly, our guideline takes several 
pathological conditions into account that might occur within the first 4 weeks of life and 
predispose to the onset of ROP.
Our model also has two disadvantages. First, a small percentage of infants with mild 
ROP will go undiagnosed. Secondly, for the group of infants with GA 30–32 weeks and/
or BW 1250–1500 g, who do not fit into the HR group, our model contains five items 
which have to be assessed. This implies extra work for the attending neonatologist or 
paediatrician. All items are, however, easily accessible and should be present in the letter 
of transfer, if patients are already discharged from the NICU before the first screening. If 
risk factors are not properly recorded, the old criteria (GA <32 weeks and/or BW <1500 
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g) should be used. External validation is essential for a new guideline.25 Validation of the 
new guideline is currently underway in the Netherlands since September 2012. Future 
studies will be necessary for monitoring the accuracy of the model, as it was based on an 
ROP inventory study in 2009. In conclusion, in the Netherlands, ROP screening may be 
reduced by adding risk factors representative for each patient’s postnatal course to the 
well known risk factors of GA and BW.
Although this implies an additional effort on the part of the neonatologist, it will reduce 
the number of infants exposed to these stressful examinations and will allow ophthal-
mologists to focus on those infants with the highest risk for ROP.
Monitoring of the new guideline is necessary.
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To investigate the cost and effects of risk factor guided screening strategies for retinopa-
thy of prematurity.
Methods
Clinical data from the Netherlands ROP study (NEDROP study), that included all infants 
screened for ROP and born in 2009 were used to assess the cost and effects of several 
screening strategies for ROP using different criteria: (1) Gestational age(GA), (2) Birth 
weight(BW), (3) combined GA-BW and (4) combined GA-BW and presence of risk factors.
Results
The most efficient screening strategy to include all infants treated for both treatment 
strategies is to screen all infants with a GA of 30 weeks or less and a BW of 1250 g or 
lower together with infants with a GA of 30-32 weeks and a BW of 1250-1500 g with at 
least one risk factor. The marginal cost ranged from €43,848 to € 226,914 per additional 
infant with improved vision.
Conclusion
The current Dutch guideline may be improved: the same effectiveness can be obtained 
for lower costs. Also releasing the precondition that no infants with severe ROP might 
be missed, will lead to lower costs, but this will also lead to a lower number of infants 
with improved visual acuity. However, the costs of detecting all infants with severe ROP 
seems acceptable for society when also including the QALY gain and savings from a 
societal perspective resulting from improved vision.
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INTRODUCTION
Retinopathy of Prematurity (ROP) is still one of the most important causes of partial sight 
or blindness in premature born infants. Various studies showed that early detection and 
treatment of ROP improve visual outcome.1
As younger and sicker infants are surviving, the number at risk for (severe) ROP increases. 
We conducted a prospective population based study, the NEDROP study, to inventor-
ize the incidence and risk factors for ROP in the Netherlands. Based on these data the 
former ROP-guideline was adjusted to focus screening on those infants with the highest 
risk of ROP and reduce the infants exposed to stressful screening examinations. The new 
screening guideline included all infants with gestational age (GA) < 30 weeks and/or 
birth weight (BW) < 1250 gram (g) as well as infants with GA 30-32 weeks and/or BW 
1250-1500 g with one of the following risk factors: artificial ventilation (AV), necrotising 
enterocolitis (NEC), sepsis, postnatal glucocorticoids or treatment with cardiotonica in 
the period between birth and the first screening examination.2 A precondition for ad-
justment of the inclusion criteria was that no infants with severe ROP would be missed. 
As costs become more and more important in health care, the aim of this study is to 
compare the effects and costs of the Dutch screening strategy with other risk factor 




Clinical data were retrieved from the Netherlands ROP study (NEDROP study), that 
included all infants screened for ROP and born in 2009. Eligible to enter this study were 
infants with GA < 32 wks and/or BW < 1500 gram. The incidence of blind and visually 
impaired children was obtained from retrospective data from the Dutch institutes of the 
visually impaired.3
ROP was classified according to the International Classification of ROP (ICROP), the high-
est stage in either eye being reported.4 For risk factor analysis the NEDROP database, 
encompassing all ophthalmological data, was merged with the Netherlands Perinatal 
Registry (PRN) which is a medical, professional based registry where pediatricians and 
neonatologists report their data of neonates born in the Netherlands.
In the NEDROP database 2193 infants were reported, of which 164 died (4 screening 
completed). Of the remaining infants, 1888 infants had a registered GA < 32 wks and/
or BW < 1500 gram, of which 1551 (82.2%) were screened for ROP. ROP developed in 
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323 (20.8 %) infants, mild ROP (stage 1 and 2) was found in 294 (19.0%) and severe ROP 
(stage ≥ 3) in 29 (1.9%) infants. Seventeen (1.1%) infants were treated.
Data analysis
Several screening strategies for ROP were studied using different criteria: (1) GA, (2) BW, 
(3) combined GA-BW and (4) combined GA-BW and presence of risk factors. An overview 
of the strategies studied is presented in table 1.
Merging of NEDROP- and PRN database was possible for 1380 infants of the 1551 that 
are included in the present study. Missing data on risk factors were substituted using 
multiple imputation by chained equations5, with 10 iterations for the switching regres-
sion model. For each missing data item, an imputation regression model was used that 
included GA, BW, treatment, presence of risk factors and ROP classification.
Using complete data the number of infants eligible for screening, severe ROP and 
treated were assessed for all screening strategies (table 1). This table was used to iden-
tify the strategies that screened the least number of infants for different numbers of 
Table 1 Number of infants eligible for screening, diagnosed with severe ROP and treated for ROP for the 
different screening strategies
Nr Criteria* Eligible Treated for ROP Severe ROP
GA, weeks
1 <26 85 7 11
2 <27 179 13 21
3 <28 313 13 22
4 <29 477 13 22
5 <30 750 15 25
6 <31 1053 16 26
7 <32 1430 17 29
BW, g
8 < 700 72 5 6
9 < 1000 342 13 19
10 < 1100 465 15 22
11 < 1200 644 15 27
12 < 1250 726 15 27
13 < 1300 806 16 28
14 < 1400 956 16 28
15 < 1500 1134 17 29
Combined, GA and BW
16 < 29/<1200 382 13 22
17 < 29/<1250 407 13 22
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Table 1 Number of infants eligible for screening, diagnosed with severe ROP and treated for ROP for the 
different screening strategies (continued)
Nr Criteria* Eligible Treated for ROP Severe ROP
18 < 29/<1500 456 13 25
19 < 30/<1200 485 14 24
20 < 30/<1250 529 14 24
21 < 30/<1500 672 15 25
22 < 31/<1200 572 15 25
23 < 31/<1250 628 15 25
24 < 31/<1500 871 16 26
25 < 32/<1200 610 15 27
26 < 32/<1250 678 15 27
27 < 32/<1500 1013 17 29
Combined, GA and/or BW
28 < 29/<1200 739 15 27
29 < 29/<1250 796 15 27
30 < 29/<1500 1155 17 29
31 < 30/<1200 909 16 28
32 < 30/<1250 947 16 28
33 < 30/<1500 1212 17 29
34 < 31/<1200 1125 16 28
35 < 31/<1250 1151 16 28
36 < 31/<1500 1316 17 29
37 < 32/<1200 1464 17 29
38 < 32/<1250 1478 17 29
39 < 32/<1500 1551 17 29
Combined GA-BW-risk factor
40 <30 wks and <1250 g and at least a risk 
factor 436 12 20
41 <32wks and <1500 g and at least a risk factor 687 15 25
Combined GA-BW-risk factor
42 <30 wks and/or <1250 g and at least a risk 
factor 666 14 24
43 <32 wks and/or <1500 g and at least a risk 
factor 899 15 25
44 < 30 wks and 1250 g OR 30-32 wks and/or 
1250-1500 g and at least a risk factor 866 17 29
45 < 30 wks and/or 1250 g OR 30-32 wks and/or 
1250-1500 g and at least a risk factor (current 
Dutch strategy) 1180 17 29
*Light	grey:	efficient	strategies	using	the	outcome	of	 the	NEDROP	study	 (17	 infants	 treated);	Dark	grey:	
efficient	strategies	using	severe	ROP	as	treatment	strategy;	Medium	grey:	efficient	strategies	for	both	the	
current treatment strategy and the severe ROP treatment strategy.
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treated infants found (efficient strategies).6 Two treatment strategies were evaluated: 
the infants actually treated in the NEDROP study (n=17) and the infants that would have 
been treated when early treatment guidelines would have been used (n=29).
Cost-effectiveness analysis
The efficient strategies were included in the cost-effectiveness analysis, in which the 
costs and effects of the different strategies were compared.
Cost of Screening
The costs resulting from the different strategies were estimated from a healthcare 
perspective. Costs are expressed in 2013 Euros. We used expert opinions to assess the 
personnel time and costs of equipment and disposables. Personnel time was valued 
using the salary costs increased with employers’ costs.7 Costs consisted of screening and 
treatment costs.
Costs of screening were assessed by multiplying the number of screening examinations 
per infant with the costs per screening. The mean number of screening examinations 
per infant was obtained from the NEDROP study8 for infants diagnosed with no ROP 
(1.2), mild ROP (4.3) and severe ROP (8.0). Costs per screening consisted of nursing costs 
(40 minutes), costs of ophthalmologist (30 minutes), eyelid speculum and eye drops, 
resulting in €109 per screening.
Costs of treatment consist of ambulance transport costs, necessary for transfer to the 
treatment center, and costs of surgery. Ambulance transport cost amount to € 2282. La-
ser treatment was performed in 82.5% of the infants and the remaining part underwent 
vitrectomy. Cost of laser treatment amount to €2,755 (costs of operating theatre use, 
2 surgery assistants, an anesthesiologist and an anesthetic nurse, an ophthalmologist 
(vitreoretinal surgeon), in 30% also a neonatologist during 105 minutes, and equipment 
costs of €31 per laser treatment) and cost of vitrectomy which amount to €5178 (costs 
of operating theatre, 2 surgery assistants, an anesthesiologist and an anesthetic nurse, 
ophthalmologist (vitreoretinal surgeon), in 30% also a neonatologist during 180 min-
utes, and equipment and disposable costs of €540).9
Effects
The effects of screening in terms of improved visual acuity depend on the improvement 
of visual acuity of early laser treatment compared to no treatment. However, only some 
smaller studies are available comparing the effects of early laser treatment with no 
treatment.10-12 We therefore obtained the effect of laser treatment from the CRYO-ROP 
en ETROP study. The CRYO-ROP study13 compared treatment with cryotherapy with no 
treatment and the ETROP compared the improved vision of early laser treatment with 
late treatment with cryotherapy.14 Using the adjusted indirect comparison method15;16, 
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we combined the improved vision of the CRYO-ROP study of 17.7% with an improved 
vision of 7.7% resulting from the ETROP study, giving an estimated improved vision of 
25.4% of laser treatment versus no treatment.13;14
RESULTS
Table 1 presents the number of infants eligible for screening, diagnosed with severe ROP 
and treated for ROP for the different screening strategies.
Table 1 shows that the most efficient screening strategy to include all infants treated for 
both treatment strategies is to screen all infants with a GA of 30 weeks or less and a BW 
of 1250 g or lower together with infants with a GA of 30-32 weeks and a BW of 1250-1500 
g with at least one risk factor. This requires screening of 866 children in the screening 
cohort.
The other shaded strategies are the most efficient strategies when detection of a lower 
number of children that need treatment would be accepted. In Table 2 the cost-effec-
tiveness of the efficient screening strategies are shown. The strategies are presented by 
ascending order of persons with improved vision. In table 2a the efficient strategies are 
shown for the infants that were treated in the NEDROP study and in table 2b for treating 
all severe ROP. Also the cost and effects of the current and previous Dutch guidelines, 
respectively screening infants with GA <30 weeks and BW <1250 g and a selection of 
infants with GA 30-32 weeks and/or BW 1250-1500 g with at least one risk factor and 
screening infants with a BW <1500 g and/or a GA <32 weeks are presented for compari-
son.
The total costs per year of the different screening programmes (including treatment 
costs) range from €58,208 for the efficient strategy detecting 5 of the 17 infants that 
were treated in the NEDROP study (strategy nr 8) to €359,106 for the efficient strategy 
that detects all 17 infants (strategy nr 44). Detecting all 17 infants will on average lead 
to an improved vision in 4.3 infants. The average cost per person with improved vision 
(AC/PIV) ranges from €43,848 per person with improved vision when screening all 
infants with a GA of 26 weeks or less (strategy nr 1) to €82,953 for the efficient screen-
ing strategy that will detect all infants that were treated in the NEDROP study (strategy 
nr 44). Some efficient strategies were dominated by other strategies, i.e. there was an 
alternative strategy or combination of alternative strategies resulting in more infants 
with improved vision for lower costs.
The marginal cost per additional PIV is the most important outcome in the cost-
effectiveness analysis. It indicates the additional cost of a unit of improved outcome of 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Detecting 7 or 13 children that need treatment, lead to marginal costs less than €100,000 
per infant with improved vision (respectively €43,848 in strategy nr 8 and €46,982 in 
strategy nr 2). However, detecting also (some of ) the other children that need treat-
ment leads to higher marginal costs ranging from €183,769 (strategy nr 10) to € 226,914 
(strategy nr 44) per additional infant with improved vision.
Total costs treating all infants with severe ROP are higher (table 2b), but as also the 
number of persons with improved vision will be higher, average and marginal cost per 
(additional) person with improved vision are lower, ranging respectively from €36,229 
(strategy nr 1) to €61,690 (strategy nr 24) and from €36,229 (strategy nr 1) to €149,647 
(strategy nr 42).
DISCUSSION
We found that even if we do not want to miss infants with severe ROP, there is a more 
efficient screening guideline than the current Dutch guideline, namely screening infants 
with GA <30 weeks and BW <1250 g and a selection of infants with GA 30-32 weeks 
and/or BW 1250-1500 g, with at least one risk factor. This screening strategy reduces 
the number of infants to be screened with 27% ((1180-866)/1180). In determining the 
current Dutch guideline a safety approach was chosen. Based on the results of 2009 
stricter inclusion criteria for screening could be chosen to reduce the number of infants 
screened while still detecting all infants with severe ROP, as illustrated by the results of 
our economic evaluation. The current guideline has led to a reduction in yearly costs of 
€77,500 compared to the previous Dutch guideline dating from 1997 advising screening 
infants with a BW <1500 g and/or a GA <32 weeks17, however further savings of €67,900 
each year might be obtained by the more stringent screening strategy resulting from 
this study.
However, the probability that in another year infants with severe ROP will be missed will 
be higher if a more stringent screening strategy is used. Therefore, it is interesting to 
investigate the stability of the current results in follow-up studies of the NEDROP, using 
data from other calendar years or in large cohorts from other countries.
If we release the precondition that no infants with severe ROP should be missed, there 
are other strategies having lower costs per infant with improved vision (see table 2). 
To decide whether we accept missing children with severe ROP, we have to determine 
which costs per additional infant with improved vision are acceptable for society. For the 
current treatment strategy these marginal costs range from €43,848 to €226,914. These 
costs should be compared to the benefits of improved vision. These benefits include 
both gains in quality of life and societal cost savings, for example due to lower educa-
tional costs as these infants don’t need special education. Assuming a mean visual acuity 
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of 0.20 in non-treated eyes and 0.48 in treated eyes18, a yearly gain in utility of 0.10 can 
be obtained according to the formula of Sharma et al.19 For an average life expectancy 
around 80 years20 and applying a discount rate of 3% over this period, this amounts to 
3.3 quality adjusted life-years (QALYs) for an infant with improved vision during lifetime. 
Relating this to the marginal costs of €226,914 results in a cost-utility ratio of €70,000 
QALY, which is high compared to the acceptable range of €20,000-€40,000 per QALY in 
the Netherlands. To reach this acceptable range, improved vision should also lead to 
cost savings of more than €100,000 during lifetime. This may be attained by savings in 
special education which amount to about €6,000 per year (personal communication). 
With an average of 15-20 years of education in the Netherlands, these cost savings will 
be attained. Next to savings in special education, also other savings may be attained for 
example in home modifications and devices and costs for carers.
Infants with improved vision will also have a higher chance of getting a paid job. Goertz 
et al evaluated unemployment among 500 clients of Royal Visio, a large institute for the 
visually disabled, and found that 36.8% had a job.21 However, when using the friction 
cost method to assess productivity costs, which is the preferred method in economic 
evaluations in the Netherlands 22;23, this will not lead to additional cost savings. Finally, 
infants born prematurely are at greater risk to have concomitant disabilities in later 
life.3;24;25 To preserve as much vision as possible in infants with ROP is important for 
lifelong independency.
In the NEDROP study not all infants with severe ROP were treated, we therefore not only 
calculated the costs and effects of the treatment practice determined in the NEDROP-
study (table 2a), but also the costs and effects if all infants with severe ROP were treated 
(table 2b), as it is expected that further implementation of the treatment guidelines 
according to ETROP will lead to the treatment of all infants detected with severe ROP. 
As shown in our analyses the efficient strategies of both treatment strategies largely 
overlap indicating that further implementation of treatment guidelines will not change 
which screening strategies are efficient in the Netherlands, but will lead to lower aver-
age and marginal cost per (additional) person with improved vision.
Several cost-effectiveness studies in retinopathy of prematurity are performed previ-
ously.6;18;26-31 Part of them compared different treatment methods26;31 or screening 
methods27;28, a single screening strategy with no treatment18 or different screening 
frequencies.30 Lee et al 20016 and Yanovitch et al29 compared different screening strate-
gies, comparable with our analysis. Lee et al6 found a screening strategy of screening 
only infants having a BW of 1200 g and less to be the most cost-effective strategy for 
routine ROP screening. In our cohort, we would have missed 2 infants treated for ROP 
using this strategy. Yanovitch et al 29 found a screening strategy with a BW <1500 g and a 
selection of infants with BW 1501 to 2000 g and greater than or equal to two significant 
risk factors to have the most favourable cost-benefit per infant screened. For our cohort, 
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this strategy would have detected all infants treated for ROP but at the expense of 1292 
children to be screened, which is 49% more than in the most efficient strategy to detect 
all infants treated for ROP.
This study has some limitations. First, the analyses are based on the outcomes of ROP 
screening of a single year (2009), repeating the analysis for another year may lead to 
different results. Secondly, the results are assessed for the Dutch situation and may not 
be directly applicable to other countries. This is illustrated by the fact that Lee et al 6 
and Yanovitch et al29 found different screening strategies to be efficient for their study 
population. In future studies the stability of the current results over time and place have 
to be assessed.
Furthermore, we used the same percentage of improved vision due to early laser treat-
ment for all children with severe ROP, independent of the ROP stage (3, 4 or 5). Also the 
use of the adjusted indirect comparison method to assess the improved vision, may be 
less reliable than a direct estimate.
In conclusion, based on our economic evaluation, the current Dutch guideline may be 
improved: the same effectiveness can be obtained for lower costs. Also releasing the 
precondition that no infants with severe ROP might be missed, will lead to lower costs, 
but this will also lead to a lower number of infants with improved visual acuity. However, 
the marginal costs of detecting all infants with severe ROP seems acceptable for society 
when also including the QALY gain and savings from a societal perspective resulting 
from improved vision.
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Retinopathy of Prematurity (ROP) is a potentially blinding disease in premature infants. 
Several risk factors associated with the development of ROP have been reported such 
as gestational age (GA), birth weight (BW), duration of artificial ventilation, sepsis and 
blood transfusions, whereas prenatal glucocorticoids would be protective. Vascularisa-
tion of the retina starts at 16 weeks and is completed around 40 weeks of gestation. 
Outgrowth of vessels is defined in 3 Zones, Zone I being the most central one.1 Vascular 
Endothelial Growth factor (VEGF) and Insuline-like Growth Factor-1 (IGF-1), produced 
by the placenta, play a crucial role in vascularisation of the retina.2 ROP is defined as 
abnormal vessel growth in the developing retina. In the first phase of ROP down regula-
tion of VEGF together with a decrease of IGF-1 causes an arrest in vessel outgrowth. 
In the second phase of ROP IGF-1 levels slowly and VEGF-levels more rapidly increase 
causing plus disease (tortuosity and dilation of retinal vessels) and neovascularizations.
Twin-Twin Transfusion Syndrome (TTTS) complicates 10-15% of monochorionic diam-
niotic twin pregnancies. This is a second report of TTTS accompanied by severe ROP 
and describes the history of two twins.4 GA, BW, risk factors and specifications about 
ROP are presented in table 1. Both donor twins showed normal weight gain and catch-
up growth. The course of development of ROP was remarkable as it developed rapidly 
although the outgrowth of retinal vessels had already progressed to peripheral zone 
II. In the first donor twin ROP stage 1 without plus disease was seen up to 39 weeks 
Post Menstrual Age (PMA) then rapidly progressing to stage 5. The second donor twin 
presented with stage 3 ROP with plus disease at the first examination.
Multiple births are unique because of the confounding effect of certain risk factors, such 
as GA and maternal risk factors, on incidence and severity of ROP. Both donor twins had 
several mild risk factors for ROP. The most striking difference between the donor and 
the recipient twins however is the number of blood transfusions given within 3 weeks 
postnatal age.
Red blood cell (RBC) transfusions are associated with an increased risk for ROP as they 
increase retinal oxygen levels by an increase in oxygen carrying capacity and a decrease 
in oxygen affinity of the red blood cell, caused by transfusing infants with adult hemo-
globin having a reduced oxygen affinity as compared to fetal hemoglobin. A second 
explanation may be that blood transfusions increase the free, non-protein bound iron 
load leading to the production of free oxygen radicals that can cause irreversible dam-
age to the developing retinal vessels.5
Last, an unintended side effect of RBC transfusions could be the concomitant administra-
tion of high doses of IGF-1. Hübler et al6 reported that the IGF-1 load in RBC transfusions 
is equivalent to a single dose of 1 μg/kg, which is 5-10% of the adult dose. Hellström et 
al showed that a rapid increase in IGF-1 together with high levels of VEGF induces rapid 
growth of new vessels.2 Based on this model, we hypothesize that artificial administra-
tion of IGF-1 via RBC transfusions causes a misbalance in IGF-1 and VEGF levels, resulting 
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in instant growth of neovascularizations in case of concomitant high levels of VEGF or 
postponement of neovascular growth when VEGF levels are low.
With this letter we want to create more awareness for those infants delivered after TTTS 
who need high numbers of RBC transfusions. Although their peripheral retina may be 
largely vascularized, they can develop potentially blinding ROP in a rapid and progres-
sive way and should therefore be monitored closely so treatment can be in time and 
blindness can be prevented.
Table 1 Characteristics of the twins
Twin 1 Twin 2
Donor Recipient Donor Recipient
Birth weight (g) 771 900 1270 1590
Gestational age (wks) 28+1 28+1 31+1 31+1
Prenatal glucocorticoïds Yes yes Yes yes
AV (days) 8 0 7 0
RDS (grade 2-3) Yes no No no
Inhaled NO Yes no No no
Transfusions 9 0 12 0
ROP
ROP stage 5 no ROP 3 no ROP
Plus disease Yes no Yes no
First screening 33+4 33+4 37+4 37+4
PMA ROP 35+3 37+4
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Despite intensive research retinopathy of prematurity (ROP) is still an important cause 
of visual impairment or blindness in prematurely born infants. The number of infants 
susceptible for severe ROP continues to rise as the gestational age of infants continues 
to decrease due to improvements in perinatal care.
It is well established that early detection and timely treatment of ROP diminishes the 
chance of developing a permanent visual disability. An evidence-based screening 
guideline is an important tool to improve early detection. However, screening guidelines 
cannot be applied universally, as level of care and risk factors differ per nation. The aim 
of this thesis was to develop a new screening guideline for the Netherlands. To minimize 
the likelihood that an infant with severe ROP would be missed, this guideline required 
easy and widespread implementation and a high predictive value..
Before any new guideline can be developed, it is vital to assess current, nationwide 
practices regarding neonatal care, ROP screening and treatment. We performed a na-
tional, prospective observational study on incidence of ROP, risk factors, ROP screening 
coherence, influence of transfers between hospitals, treatment criteria and practices: 
the NEDROP study.
First we investigated the incidence of infants with a visual disability due to ROP that 
were registered in the Institutes for the visually impaired in the Netherlands. Chapter 2 
describes a follow up study of three earlier Dutch studies and presents a 30 year over-
view of visual impairment due to ROP in the Netherlands. In addition to the incidence of 
visual impairment (VI) caused by ROP, concomitant disabilities in preterm neonates born 
between 2000 and 2009 were evaluated using data obtained from the Dutch Institutes 
for the visually impaired. In the study group of 42 infants with ROP (or visual impair-
ment), we observed a gradual decrease of gestational age (GA) and birth weight (BW), an 
increase of duration of artificial ventilation (AV), supplemental oxygen administration, 
bronchopulmonary dysplasia (BPD), developmental delay, and behavioral abnormali-
ties. Compared with the previous study (1994-2000), significantly fewer children were 
visually impaired due to ROP and the incidence of complete blindness significantly 
decreased. Although more children received treatment, one third did not. The incidence 
of concomitant disabilities remained remained unchanged (73.8 vs 68.6%).
Screening logistics and ophthalmological data of the NEDROP study are presented in 
Chapter 3. Participation in the NEDROP study was high: all screening ophthalmologists, 
neonatologists, and pediatricians of the neonatal intensive care units (NICU’s) and high 
care centers (HC’s) and one third of pediatricians of regional centers participated. All 
infants born with a GA <30 weeks and 85%-90% of infants with GA 30-32 weeks are ad-
mitted to a NICU. Therefore, our study provided good insight into screening logistics and 
incidence of ROP in the Netherlands. In total, 2033 infants were reported of which 1688 
(83%) were screened. ROP developed in 324 infants (19.2%), with a low incidence of se-
vere ROP (30 infants (1.8%)) of which only 17 infants (1%) were treated. Difficulties with 
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retrospective classification of infants in type 1 and 2 ROP suggested that ETROP criteria 
for treatment were not universally implemented at the time of the NEDROP study. The 
median post menstrual age (PMA) when ROP was first detected was 34.1 weeks. In 641 
cases (38%), the initial screening examination was not performed within the required 42 
days. In 99.2% of all cases, the date for follow up was accomplished within 3 days of the 
planned date. Transfer to another hospital increased the chance of not being screened 
from 12.9% to 25% in case of three transfers.
The reported data by neonatologists and pediatricians (GA, BW, date of birth, zip code 
and numbered multiple births), enabled coupling of our NEDROP database to the al-
ready existing perinatal registry. Yearly, more than 95% of infants born <32 weeks’ gesta-
tion are reported to the Netherlands Perinatal Registry. Of the 1561 infants with GA <32 
weeks and/or BW <1500 g reported in the NEDROP study, 1380 could be linked (88%) to 
the perinatal registry. Based on these data, a risk factor analysis was performed (Chapter 
4). Similar to previous studies, a lower incidence of ROP was observed in females and 
after prenatal administration of glucocorticoids. We also confirmed previously reported 
risk factors including GA, BW, length of stay at a NICU > 28 days and Artificial Ventila-
tion (AV) > 7 days. In addition, we found that treatment with inhaled nitric oxide (iNO) 
presented a risk factor for ROP development. Inhaled NO is commonly administered to 
the most severely ill neonates, and is a relatively new rescue therapy.
We then developed a new guideline with the aim to reduce the number of infants 
that require screening (Chapter 5), since screening is stressful to the neonate and 
time-consuming for the care-giver. Screening criteria were developed to assure that no 
infants with severe ROP were missed: GA <30 weeks and/or BW <1250g and a selection 
of infants with GA 30-32 weeks and/or BW 1250-1500g, with at least one of the following 
risk factors: AV, sepsis, necrotizing enterocolitis (NEC), postnatal glucocorticoids or use 
of cardiotonics. Applying these new criteria to our study group resulted in a 29% reduc-
tion in screening, at the cost of not detecting 4.8% infants with mild ROP but without 
missing any infants with severe ROP. This reduced the number of fundoscopies by 21%.
The final analysis conducted with the NEDROP data represents a cost-effectiveness 
study (Chapter 6). With increasing awareness for costs in health care, the aim was set 
to compare the effects and costs of the Dutch screening strategy with other risk factor 
guided screening strategies, including also strategies in which not all infants with severe 
ROP are detected. It proved possible to improve the cost effectiveness of the current 
Dutch guideline by screening infants with GA <30 weeks and BW <1250 g, and infants 
with GA 30-32 weeks and/or BW 1250-1500 g with one of the previously described risk 
factors. This screening strategy reduced the number of infants to be screened by 27%. 
Compared to the previous Dutch guideline dating from 1997, the current guideline has 
reduced yearly costs by €77,500. However additional yearly savings of €67,900 might be 
obtained by even more stringent screening strategy as shown in this study.
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Even lower costs would be achieved by leaving out the requirement of not missing out 
on infants with severe ROP. However, this will increase the chance of missing infants with 
severe ROP and may therefore reduce the number of infants with improved visual acuity. 
As this poses ethical questions and infants with improved vision have a higher chance 
of getting a paid job and live independently, a safety approach was chosen when the 
criteria for the current Dutch guideline were set.
In Chapter 7, a special subgroup at risk for severe ROP is highlighted. Donors with twin-
twin transfusion syndrome (TTTS) developed severe ROP, in contrast with the receiver 
twin who does not develop ROP at all. A large number of blood transfusions convene a 
possible deleterious effect by simultaneous suppletion of IGF-1 administered via these 
blood transfusions. Although their peripheral retina may be largely vascularized, they 
can develop potentially blinding ROP in a rapid and progressive way and should there-
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The overall goal of our study was to establish a guideline to optimize care for infants 
at-risk for development of retinopathy of prematurity (ROP). Before we started our 
prospective inventory, a retrospective study was performed to evaluate the number of 
infants with permanent visual disability due to ROP in the Netherlands. Three previous 
studies performed a similar assessment. We combined all data to provide an overview 
of more than thirty years of ROP in the Netherlands, reflecting changes in neonatal 
care and treatment policies in our country. A decrease was observed in children with 
visual impairment due to ROP, the percentage of concomitant and multiple disabilities 
remained high. One third of at-risk infants was not treated.
To obtain insight in the current status of ROP and the logistics involved in screening 
and care for premature born infants, we initiated a national prospective inventory: the 
NEDROP-study. In this study, which included 2033 infants, 83% of the population was 
screened and ophthalmological data could be coupled to perinatal data in 88%. The in-
cidence of ROP was 19%. Transfer to another hospital increased the risk for loss to follow-
up. In addition, ETROP criteria for treatment turned out to be not well applied since 12 
out of 29 infants with severe ROP were not treated. By coupling the NEDROP database to 
the existing perinatal registry, we identified treatment with inhaled nitric oxide as a new 
risk factor for ROP in addition to already established risk factors as BW, GA, stay at a NICU 
> 28 days and AV > 7 days. Based on this risk factor analysis, an overview of the literature 
and the precondition that no infants with severe ROP should be missed, a new screening 
guideline for the Netherlands was developed. Using this new guideline the number of 
infants who require eye examinations can be reduced by 29% and more focus can be put 
on those infants with the highest risk for ROP. Cost effectiveness analysis showed that 
our new screening criteria are efficient, the marginal cost ranging from 43.000–226.000 
euro per additional infant with improved vision. These costs are acceptable for society 
when also the QALY gain and savings from a societal perspective are included, resulting 
from improved vision obtained through treatment in time after timely detection.
RECOMMENDATIONS FOR THE FUTURE
Two recent changes in neonatal care are expected to increase the number of infants at 
risk to develop (severe) ROP in the Netherlands: 1) the change in resuscitation policy 
in our country: since the end of 2010 the advised resuscitation level was lowered from 
25 weeks GA to 24 weeks GA1, and 2) the new oxygen saturation level recommenda-
tions from the Neoprom meta-analysis.2 These changes in treatment in neonatal care 
are also expected to increase the number of infants needing treatment and might have 
consequences for our screening and treatment strategy. Therefore, close monitoring of 
our data in future is mandatory, as well as monitoring the incidence of blind- and poor-
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sighted infants known at the Dutch Institutes for the visually impaired. To ensure that 
the number of infants with visual impairment will continue to decrease over the coming 
years, it is required that at-risk neonates are screened, followed-up and treated in a 
timely manner. This also includes the twins with TTTS. These infants need to be investi-
gated on larger scale. In addition, close collaboration between all professionals involved 
in the care and screening for ROP in premature infants is critical. Implementation of our 
newly developed guideline should facilitate good ROP practice, and should be evalu-
ated within a few years. We also need to monitor if the reduction in screening, achieved 
with our new guideline, is safe or even can be reduced further. We therefore are engaged 
in the implementation of a (web-based) database to provide and retrieve up-to-date 
information about infants screened for ROP in the Netherlands. This will facilitate the 
detection of changes in incidence of ROP and severe ROP and call for modification of 
the guideline when required. Also, education and information about ROP is of prime 
importance. To provide such support, we developed an app that will be instrumental 
in delivering information about need of screening for an infant for neonatologists. An 
app that will facilitate import of data to the aforementioned web-based database for 
ophthalmologists is under construction.
Furthermore, an e-learning was developed to implement the current guideline, yielding 
CME credits for ophthalmologists.
Even though not covered by my thesis, it will be of great importance to investigate 
prevention and new treatment modalities.
As treatment in any form is substantial to prevent blindness, but not addressing the 
underlying cause, the possibility of preventing ROP should be further investigated. 
Several studies are underway to evaluate the effect of possible preventing factors, with 
the primary endpoint to get a reduction or elimination of severe ROP.
A pharmacokinetic and dosing study of intravenous IGF-1–IGFBP3 complex in preterm 
infants, showed no adverse effects and an increase in serum IGF-1 to in-utero concentra-
tions.
Furthermore, granulocyte colony-stimulating factor (GCSF) a biologic cytokine to 
increase leukocyte counts, has been shown to increase levels of IGF-1, which supports 
normal vasculogenesis. So, GCSF may promote angiogenesis in ischemic retina without 
any known negative effect on VEGF.
Supplementing ω-3 long-chain polyunsaturated fatty acids reduces the risk of ROP in 
mice. An increased retinal omega-3 and omega-6 PUFA ratio had 50% protective effect 
against pathologic neovascularization due to increased regrowth of vessels after vessel 
loss.
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More knowledge needs to be gained through preclinical studies regarding anti-
angiogenic treatment in ROP, including dose, type, and safety. Not only do we need 
more knowledge about treatment with bevacizumab, also other anti-VEGF agents like 
pegaptanib (Macugen®) for partial blockage of VEGF-A, or drugs such as ranibizumab 
(Lucentis®) and aflibercept (Eylea®) for pan-VEGF-A blockage, need to be investigated.
Gene therapy shows promising results in mice, by targeting and regulation of various cy-
tokines and growth factors known to be involved in the pathogenesis of ROP. However 
the safety of gene application therapy and its possible effects to a developing preterm 
infant are uncertain and have yet to be fully evaluated.
Improvement of screening as well as treatment together with better prevention of 
ROP will hopefully result in a decrease of visual impairment in preterm infants in the 
Netherlands. This will improve their quality of life and contribute to their independence. 
It would be of much importance if this could be demonstrated in NEDROP-2.
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Bij veel te vroeg geboren kinderen blijft prematurenretinopathie (ROP) een belangrijke 
oorzaak van blind- en slechtziendheid. Dit ondanks uitgebreid onderzoek. De oorzaak 
hiervan is, dat de leeftijd, waarop deze kinderen geboren en in leven gehouden kunnen 
worden daalt door een betere neonatologische behandeling. Het aantal kinderen, dat 
ernstige ROP kan oplopen neemt hierdoor toe. Een vroege opsporing en behandeling 
van ROP kan de kans op het ontwikkelen van een visuele beperking en de ernst daarvan 
verminderen.
Een evidence-based richtlijn is een belangrijk hulpmiddel om de zorg voor deze hoog-
risico prematuren te optimaliseren. Er is echter geen universeel screeningsprotocol op 
te stellen, omdat het niveau van de neonatologische zorg per land erg kan verschillen. 
Het doel van deze studie was om een nieuwe screeningsrichtlijn op te stellen voor 
Nederland die voldoet aan de volgende voorwaarden: relatief eenvoudig te implemen-
teren en een hoog voorspellende waarde heeft zodat geen enkel kind met ernstig ROP 
gemist zal worden.
Voordat een nieuwe richtlijn kan worden ingevoerd is het van belang om eerst de 
huidige werkwijze ten aanzien van de neonatale zorg, ROP screening en behandeling 
vast te stellen. Daarom werden op nationaal niveau het screeningsproces, de invloed 
van overplaatsingen, de incidentie van ROP, de risicofactoren alsmede de behandelcri-
teria en de behandeling van ROP geïnventariseerd door middel van de NEDROP studie 
(hoofdstukken 3-6).
Hoofdstuk 2 beschrijft een follow up studie van drie eerdere Nederlandse studies en 
geeft een dertigjarig overzicht van de visuele gevolgen van ROP. Daarnaast worden 
aan de hand van gegevens van de Nederlandse Instituten voor visueel gehandicapten, 
ook bijkomende handicaps geïnventariseerd bij prematuren geboren in Nederland 
tussen 2000 en 2009. Deze groep (2000–2009) deze groep, bestaande uit 42 kinderen, 
werden een geleidelijke daling van de zwangerschapsduur (GA), het geboortegewicht 
(BW), een toename van de duur van kunstmatige ventilatie (AV), het toedienen van 
zuurstof, bronchopulmonaire dysplasie (BPD) en een achterstand in de ontwikkeling 
en gedragsstoornissen gevonden. Vergeleken met vorige studies (1994-2000), waren 
er significant minder kinderen visueel gehandicapt ten gevolge van ROP en was ook 
de incidentie van totale blindheid gedaald van 27.5% tot 7.1% (p<0.05). Hoewel het 
aantal behandelde kinderen toenam, werd een derde niet behandeld. De incidentie 
van bijkomende handicaps bleef hoog op een redelijk constant niveau (73,8% vs 
68,6%).
In Hoofdstuk 3 wordt de logistiek van de NEDROP studie beschreven met betrekking tot 
de verkregen screenings- en oogheelkundige gegevens. De deelname aan de NEDROP 
studie was hoog: alle screenende oogartsen, neonatologen en kinderartsen van de 
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neonatale intensive care afdelingen (NICU’s) en de high care centra (HC’s) en 1/3 van de 
regionale centra deden mee.
Alle kinderen, geboren met een GA<30 weken en 85-90 % van de kinderen met een 
GA van 30-32 weken zijn op een NICU opgenomen. Deze hoge participatie en inclusie 
geven daarom een goed inzicht in de logistiek van screening en in incidentie van ROP. 
Van de 2033 kinderen, die werden aangemeld werd 83% gescreend. In 324 kinderen 
(19,2%) ontwikkelde zich ROP. De incidentie van ernstige ROP was met 30 kinderen 
(1,8%) laag. Hiervan werden 17 kinderen (1%) behandeld. Moeilijkheden bij de retro-
spectieve indeling van kinderen in type 1 en type 2 ROP doen vermoeden, dat de ten 
tijde van de NEDROP studie geldige ETROP criteria voor behandeling niet overal waren 
geimplementeerd.
De mediane post menstruele leeftijd (PMA) waarop ROP voor het eerst werd vastgesteld 
was 34.1 weken. In 642 gevallen (38%) werd de eerste screening niet uitgevoerd binnen 
de vereiste 42 dagen post natale leeftijd, terwijl in 99,2% de follow up afspraak wel bin-
nen een periode van 3 dagen van de afgesproken datum viel.
Overplaatsing naar een ander ziekenhuis verhoogde de kans om niet gescreend te 
worden van 12,9% naar 25% in het geval van drie overplaatsingen.
Alle door de neonatologen en kinderartsen verstrekte gegevens (GA, BW, geboorteda-
tum, postcode en of er sprake is van een meerling) maakten een koppeling mogelijk 
van de NEDROP database met de al bestaande Perinatale Registratie Nederland (PRN), 
waar jaarlijks meer dan 95% van de kinderen geboren bij een GA <32 weken wordt 
aangemeld.
Van de 1561 kinderen met een GA < 32 weken en/of een BW<1500 gram, die aangemeld 
werden in de NEDROP studie konden 1380 kinderen (88%) gekoppeld worden aan de 
gegevens van de PRN.
In Hoofdstuk 4 worden op basis van deze gegevens de risicofactoren geïdentificeerd 
en geanalyseerd. Hierbij werd net als in de literatuur een lager risico op ROP gevonden 
bij meisjes en na het prenataal toedienen van glucocorticosteroiden. Ook de al eerder 
gerapporteerde risicofactoren als GA, BW, duur van de opname op een NICU > 28 dagen 
en een kunstmatige beademing > 7 dagen werden bevestigd. Nieuw was de bevinding 
dat ook de behandeling met stikstof oxide (iNO) een risicofactor op het ontwikkelen van 
ROP bleek te zijn. Deze iNO behandeling is betrekkelijk nieuw en wordt toegepast bij de 
ernstigst zieke neonaten.
Op basis van alle resultaten, die uit deze gegevens naar voren zijn gekomen werd een 
nieuw screeningsprotocol geschreven. Uitgangspunten hierbij waren, dat er geen enkel 
kind met ernstige ROP gemist mocht worden en dat het aantal screeningsmomenten 
beperkt moest worden. Screeningsonderzoek is stressvol voor het kind en tijdrovend 
voor de oogarts. In Hoofdstuk 5 wordt de uitwerking van het opstellen van een risico-
factoren model beschreven en de nieuwe richtlijn bevat de volgende screeningscriteria: 
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GA< 30 weken en/of een BW<1250 gram en een selectie van kinderen met GA 30-32 
weken en/of een BW van 1250-1500 gram met tenminste een van van de volgende risi-
cofactoren: AV, sepsis, necrotiserende enterocolitis (NEC) en het postnataal behandelen 
met glucocoticosteroiden of cardiotonica.
Uit toepassing van dit nieuw ontwikkelde screeningsprotocol op onze studiegroep 
bleek een screeningsreductie van 29% mogelijk ten koste van het niet opsporen van 
4.8% van de kinderen met een milde ROP maar met behoud van het opsporen van alle 
kinderen met ernstige ROP.
Tot slot werd op basis van de NEDROP gegevens een kosten-effectiviteits analyse 
uitgevoerd. In Hoofdstuk 6 wordt een kosten-effectiviteits analyse beschreven, die op 
basis van de NEDROP gegevens werd uitgevoerd. Het doel van deze studie was om de 
kosten van dit Nederlandse screeningsprotocol te vergelijken met andere screenings 
protocollen op basis van risicicofactoren of minder strenge eisen aan de opsporing van 
kinderen met ernstige ROP.
De kosten-effectiviteit van het huidige Nederlandse protocol verbeterde bij screening 
van kinderen met een GA< 30 weken en een BW< 1250 gram en kinderen met een GA 
van 30-32 weken en/of een BW van 1250-1500 gram met een van de al beschreven 
risicofactoren.
De screeningsstrategie deed het aantal te screenen kinderen met 27% afnemen. Verge-
leken met het Nederlandse protocol uit 1997 verlaagde het huidige protocol de kosten 
met 77.500 euro per jaar. Een stringenter screeningsprotocol kan hierbovenop nog een 
besparing van 67.900 euro per jaar opleveren.
Als men de eis, dat er geen kinderen met ernstige ROP gemist mogen worden, laat 
vallen kunnen de kosten verder omlaag. Dit doet dan de kans toenemen om kinderen 
met ernstige ROP te missen en kan dus het aantal kinderen met een verbeterde visus-
scherpte doen afnemen. Omdat dit ethische vragen oproept en omdat kinderen met 
een betere visus een grotere kans hebben op een betaalde baan en een onafhankelijk 
bestaan is voor de veilige criteria gekozen bij het opstellen van het huidige Nederlandse 
screeningsprotocol.
In Hoofdstuk 7 wordt een speciale groep kinderen met een verhoogde kans op ernstige 
ROP besproken. Bij het tweeling transfusie syndroom (TTS) ontwikkelden de donor 
kinderen ernstige ROP in tegenstelling tot de ontvangende tweeling, die helemaal geen 
ROP ontwikkelde. Een groot aantal bloedtransfusies heeft mogelijk een averechts effect, 
doordat hiermee extra IGF-1 wordt toegevoegd. Hoewel de perifere retina van deze 
kinderen uitgebreid gevasculariseerd is, kunnen zij op een snelle en sterk progressieve 
wijze een potentieel blindheid veroorzakende ROP ontwikkelen. Deze kinderen moeten 
zeer nauwlettend gemonitord worden, zodat op tijd met de behandeling gestart kan 
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SAMENVATTING RICHTLIJN PREMATURENRETINOPATHIE
(Goedgekeurd tijdens de Algemene Ledenvergadering van het Nederlands Oog-
heelkundig Gezelschap (NOG) in maart 2013.)
In onderstaande samenvatting staat een opsomming van de uitgangsvragen en aanbe-
velingen die in de richtlijn zijn beschreven betreffende prematurenretinopathie.
Uitgangsvraag 1
Wat zijn de inclusie criteria voor het screenen op ROP?
- Welke kinderen ontwikkelen ROP en hoeveel kinderen ontwikkelen een ernstige 
ROP?
- Wat zijn de perinatale risicofactoren voor het ontwikkelen van ROP?
De werkgroep adviseert ROP-screening van de volgende kinderen:
-  Alle kinderen met een zwangerschapsduur < 30 weken en/of geboorte gewicht < 1250 gram.
-  Alle kinderen met een zwangerschapsduur tussen de 30-32 weken en/of een geboorte gewicht tus-






-  Als differentiatie met de beschreven risicofactoren niet betrouwbaar uit te voeren is, wordt screening 
geadviseerd van:
	 •	 	Alle	 kinderen	met	 een	 zwangerschapsduur	 <	 32	weken	 en/of	 een	 geboorte	 gewicht	 <	 1500	
gram.
De werkgroep adviseert terugkoppeling van de bevindingen van screening door de oogarts aan kin-
derarts en verpleging om de bevindingen mee te kunnen wegen bij het beleid en optimaal monitoren 
van de zuurstofsaturatie te waarborgen.
Uitgangsvraag 2
Welk screeningsschema moet gehanteerd worden?
- Vanaf welke Post Menstrual Age (PMA) of Post Natal Age (PNA) moet gestart worden 
met screenen?
- Welke screeningsfrequentie wordt geadviseerd?
1e screening:
5 weken (35 - <42 dagen) na de geboorte maar niet voor 31 weken PMA:
Zwangerschapsduur 24 weken: 7 weken na geboorte
Zwangerschapsduur 25 weken: 6 weken na geboorte




ROP met plus disease wanneer besloten wordt nog niet te 
behandelen (zie H 4)
Meer dan 1x per week
Avasculair in zone I
ROP 1 of 2 in zone I, geen plus
ROP 2 of 3 in zone II, geen plus
ROP in regressie, zone I
Fundus onvoldoende te beoordelen
Wekelijks
Avasculair zone II, geen ROP
ROP 1 zone II
ROP 1 of 2 zone III
ROP in regressie, zone II en zone III
1x per 2 weken













gestaakt is bij niet volledige vascularisatie.
Wanneer afgeweken wordt van de richtlijn dient men dit met reden te vermelden in het dossier van het 
kind. De hoofdbehandelaar bespreekt de mogelijke afwegingen met de ouders. Zo nodig dient onder-
zoek alsnog zo snel mogelijk gepland te worden.
Uitgangsvraag 3
Wat zijn de overwegingen bij overplaatsing en verwijzing?
- Wat zijn de overwegingen bij overplaatsing op niet-oogheelkundige gronden naar 
een ander ziekenhuis
- Wat zijn de overwegingen bij overplaatsing, op oogheelkundige gronden, naar een 
ziekenhuis met meer faciliteiten en/of expertise (academisch of regionaal)
Beslisboom: overplaatsing op niet oogheelkundige gronden naar ander centrum:
1) Bij geboorte: kalenderweek waarin screening plaats moet vinden wordt vastgelegd
2) Screening vindt plaats volgens protocol
3) Overplaatsing aan de orde en screening nog niet afgerond?
	 •	 	Inschatten	risico	op	ROP
	 •	 	Kinderarts	/	neonatoloog	overlegt,	zo	nodig,	met	kinderarts	/	neonatoloog	in	ontvangende	zie-
kenhuis om te bepalen of:
	 •	 	Voldoende	expertise	en	continuïteit	aanwezig?
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Ja: Overplaatsen
Nee: Niet overplaatsen naar dit centrum
Overplaatsing naar een centrum met meer faciliteiten en/of expertise?*
1) Als beoordeling en/of behandeling in het betreffende centrum niet mogelijk is
2) Als sprake is van onduidelijkheid over stagering en/of beloop
Als behandeling noodzakelijk is en in het huidige centrum onvoldoende faciliteiten en/of expertise 
voor behandeling aanwezig zijn
Geadviseerd wordt om regionale afspraken te maken over het overplaatsingsbeleid van prematuren 
met een verhoogd risico op ROP.
Toelichting:
* Centrum met faciliteiten en/of expertise voor screening:
-  Expertise en logistiek voor ROP screening is aanwezig en neonatologische zorg passend bij de ernst 
van de situatie kan geboden worden.
- De continuïteit van de screening (NB absenties van oogarts, waarneming) is gewaarborgd.
Uitgangsvraag 4
Bij welke criteria moet ROP behandeld worden?






Type 2 ROP: Dient nauwlettend in de gaten gehouden te worden.
•	 ROP	1	of	2,	zone	I	zonder	plus	disease
•	 ROP	3	zone	II	zonder	plus	disease
Laagdrempelig overleg met een centrum met ROP expertise wordt geadviseerd.
Bij ernstige ROP en behandeling van ROP verdient het aanbevelingen de situatie vast te leggen met 
fundusfoto’s.
Transpupillaire laser is de behandeling van eerste keus.
Behandeling van ROP dient uitgevoerd te worden door een oogarts met ervaring op dit gebied.
Uitgangsvraag 5
Welke logistieke aspecten tav ROP screening zijn van belang om het proces efficiënt te 
laten verlopen?
- Randvoorwaarden afdeling / ziekenhuis voor screening:
 - Verpleegkundig personeel
 - Materieel
 - Screenende oogartsen
- Hoe wordt de eerste screeningsafspraak geregeld?
- Hoe wordt gezorgd voor optimale mydriasis?
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- Wie is verantwoordelijk voor het regelen van follow-up van screening bij overplaat-
sing van een kind?
- Hoe wordt de overdracht van informatie geregeld naar collegae?
De screening dient zo snel mogelijk uitgevoerd te worden, gedurende het onderzoek moet de alge-
mene conditie van het kind in de gaten gehouden worden.
De oogarts wordt geassisteerd door een ervaren zorgverlener zodat tijdens de screening het kind goed 
gepositioneerd wordt en het onderzoek naar behoren kan worden uitgevoerd.
Voor optimaal comfort van het kind adviseert de werkgroep dat tenminste 30 seconden voor het plaat-
sen van de ooglidspreider een lokaal anaestheticum wordt toegediend.
De screening dient zo comfortabel als mogelijk te verlopen, dit kan door middel van juiste positione-
ring, sucrose, speen en / of inbakeren van het kind.
Er dienen lokale afspraken gemaakt te zijn over hoe de logistiek in het ziekenhuis geregeld is betref-
fende het maken van de eerste- en de vervolg screening en het opvangen van acute situaties.
Met het toedienen van mydriatica dient 1 uur voor screening begonnen te worden. Beiderzijds 1 drup-
pel tropicamide 0.5% en 1 druppel fenylefrine 2.5%, dit wordt na 15 minuten herhaald en dient in totaal 
2 of 3 keer te gebeuren. Als de pupil niet wijd wordt dient de oogarts geïnformeerd te worden.
De hoofdbehandelaar is verantwoordelijk voor de juiste informatievoorziening voor follow-up bij over-
plaatsing van een kind.
Na screening dienen de volgende gegevens op het consultvel te staan:
- bij onvolledige vascularisatie zone aangeven
- bij ROP de graad en zone, aanwezigheid van (pre)-plus disease
- vervolg van screening
- mogelijke behandeling
In de overplaatsingsbrief van de kinderarts dient specifieke informatie over ROP vastgelegd te zijn: 
bevindingen bij onderzoek en afspraken over vervolgscreening of vermelding dat screening nog 
niet heeft plaats gevonden. Geadviseerd wordt om de kalenderweek te vermelden waarin (vervolg)
screening moet plaatsvinden.
Uitgangsvraag 6
Hoe worden ouders geïnformeerd?
- Over screening en schema
- Bevindingen van screening
- Over ROP
Er wordt een begrijpelijke, informatieve ROP folder aan de ouders uitgereikt voordat de eerste screening 
zal plaatsvinden.
Informeer de ouders over dag(deel) waarop de screening plaats vindt.
Zorgverleners bepalen in samenspraak met de ouders of deze bij de screening aanwezig zullen zijn.
Na de screening worden de ouders van de bevindingen op de hoogte gesteld. Bij (dreigende) ernstige 
afwijkingen gebeurt dit in principe door de oogarts.
In het dossier wordt een notitie gemaakt over de inhoud van het gesprek met de ouders.












•	 Drs.	 G.J.	 van	 Steenbrugge,	 directeur	 Vereniging	 Ouders	 van	 Couveusekinderen,	
Leidschendam.




Als er bij uw kind ROP is ontstaan zijn er twee mogelijkheden:
1. De ROP verdwijnt spontaan en de bloedvaten groeien alsnog op een normale wijze 
door. Gelukkig gebeurt dit bij het merendeel van de kinderen. 
2. De ROP gaat steeds een stadium verder.
Na de screening wordt u door een zorgverlener van de bevindingen op de hoogte ge-
bracht. Bij (dreigende) ernstige afwijkingen gebeurt dit door een oogarts.
Behandeling
Bij een klein aantal kinderen zal er vervolgens behandeling nodig zijn. Doorgaans is dit 
een laserbehandeling die kan worden uitgevoerd in een aantal gespecialiseerde cen-
tra. Het kan dus zijn dat uw kindje tijdelijk moet worden overgeplaatst naar een ander 
ziekenhuis. Met deze behandeling wordt het deel van het netvlies dat zuurstoftekort 
heeft uitgeschakeld, waardoor de productie van de stofjes, die de uitgroei van bloedva-
ten stimuleren, af neemt. Soms lukt dit onvoldoende wat kan betekenen dat nogmaals 
behandeling nodig is. In een enkel geval kan het voorkomen, dat ondanks alle inspan-
ningen een kindje toch blind- of slechtziend wordt. 
Uw kind
Wanneer er voor uw kind een afspraak ten behoeve van screening op ROP is ingepland, 
wordt u hierover geïnformeerd. U hoort op welke dag of dagdeel de screening plaats 
vindt. 
Een onderzoek bij uw kindje kan vervelend zijn om te zien, maar het kan voor uw kind 
prettig zijn als u er wel bij bent. Overleg daarom met de zorgverleners van de afdeling of 
u bij het onderzoek aanwezig zult zijn. 
Als uw kind overgeplaatst wordt, zullen de gegevens inclusief de termijn voor het eventu-
ele vervolgonderzoek doorgegeven worden aan het volgende ziekenhuis. Mocht uw kind 
naar huis gaan en nog gescreend moeten worden dan krijgt u daarvoor een afspraak 
mee. Mocht deze afspraak echt niet door kunnen gaan dan moet op korte termijn een 
nieuwe gemaakt worden.
Wij willen u graag het belang van ROP-screening uitleggen. Het kan zijn dat dit met 
deze folder niet helemaal gelukt is en u toch nog met vragen bent blijven zitten. Raad-
pleeg in dat geval gerust uw arts voor verdere informatie. 
Uw artsen
U heeft contact gehad met: 







Het netvlies (retina) is een onderdeel van het oog dat essentieel is voor het zien. De 
bloedvaten die dit netvlies van voeding voorzien zijn pas in de laatste weken van de 
zwangerschap volgroeid. Bij een te vroeg geboren kind zullen deze bloedvaten in de 
eerste levensmaanden dus nog moeten uitgroeien. Door veel oorzaken kan de normale 
groei van deze bloedvaten verstoord worden. Er is dan sprake van prematurenretinopa-
thie, ook wel ROP genoemd. 
Waarom worden te vroeg geboren kinderen oogheelkundig onderzocht?
Bij een klein aantal kinderen met ROP ontstaat een ernstige vorm die behandeld moet 
worden. Met deze behandeling wordt geprobeerd om blind- of slechtziendheid te voor-
komen. Om die behandeling tijdig te kunnen uitvoeren is het belangrijk dat ROP in een 
vroeg stadium herkend wordt. Dit gebeurt door middel van een oogonderzoek.
Welke kinderen worden gescreend?
Kinderen die bij hun geboorte minder dan 1250 gram wegen en/of geboren zijn na een 
zwangerschapsduur die korter is dan 30 weken
en
Kinderen die bij hun geboorte tussen de 1250 gram en 1500 gram wegen en/of gebo-
ren zijn na een zwangerschapsduur tussen de 30 en 32 weken, die één van de volgende 
behandelingen / aandoeningen hebben gehad: beademing, sepsis, necrotiserende 
enterocolitis (NEC), behandeling met bepaalde medicijnen (cardiotonica) vanwege lage 
bloeddruk of behandeling met corticosteroïden na de geboorte. 
ROP screening
U krijgt deze folder omdat uw kind gescreend 
moet worden op een oogaandoening: 
prematurenretinopathie. Hierin kunt u 
nog eens nalezen waarom dit onderzoek 
noodzakelijk is bij uw kind.
Deze folder is tot stand gekomen in samenwerking met:
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AAls er bij uw kind ROP is ontstaan zijn er twee mogelijkheden:
1. De ROP verdwijnt spontaan en de bloedvaten groeien alsnog op een normale wijze 
door. Gelukkig gebeurt dit bij het merendeel van de kinderen. 
2. De ROP gaat steeds een stadium verder.
Na de screening wordt u door een zorgverlener van de bevindingen op de hoogte ge-
bracht. Bij (dreigende) ernstige afwijkingen gebeurt dit door een oogarts.
Behandeling
Bij een klein aantal kinderen zal er vervolgens behandeling nodig zijn. Doorgaans is dit 
een laserbehandeling die kan worden uitgevoerd in een aantal gespecialiseerde cen-
tra. Het kan dus zijn dat uw kindje tijdelijk moet worden overgeplaatst naar een ander 
ziekenhuis. Met deze behandeling wordt het deel van het netvlies dat zuurstoftekort 
heeft uitgeschakeld, waardoor de productie van de stofjes, die de uitgroei van bloedva-
ten stimuleren, af neemt. Soms lukt dit onvoldoende wat kan betekenen dat nogmaals 
behandeling nodig is. In een enkel geval kan het voorkomen, dat ondanks alle inspan-
ningen een kindje toch blind- of slechtziend wordt. 
Uw kind
Wanneer er voor uw kind een afspraak ten behoeve van screening op ROP is ingepland, 
wordt u hierover geïnformeerd. U hoort op welke dag of dagdeel de screening plaats 
vindt. 
Een onderzoek bij uw kindje kan vervelend zijn om te zien, maar het kan voor uw kind 
prettig zijn als u er wel bij bent. Overleg daarom met de zorgverleners van de afdeling of 
u bij het onderzoek aanwezig zult zijn. 
Als uw kind overgeplaatst wordt, zullen de gegevens inclusief de termijn voor het eventu-
ele vervolgonderzoek doorgegeven worden aan het volgende ziekenhuis. Mocht uw kind 
naar huis gaan en nog gescreend moeten worden dan krijgt u daarvoor een afspraak 
mee. Mocht deze afspraak echt niet door kunnen gaan dan moet op korte termijn een 
nieuwe gemaakt worden.
Wij willen u graag het belang van ROP-screening uitleggen. Het kan zijn dat dit met 
deze folder niet helemaal gelukt is en u toch nog met vragen bent blijven zitten. Raad-
pleeg in dat geval gerust uw arts voor verdere informatie. 
Uw artsen
U heeft contact gehad met: 







Het netvlies (retina) is een onderdeel van het oog dat essentieel is voor het zien. De 
bloedvaten die dit netvlies van voeding voorzien zijn pas in de laatste weken van de 
zwangerschap volgroeid. Bij een te vroeg geboren kind zullen deze bloedvaten in de 
eerste levensmaanden dus nog moeten uitgroeien. Door veel oorzaken kan de normale 
groei van deze bloedvaten verstoord worden. Er is dan sprake van prematurenretinopa-
thie, ook wel ROP genoemd. 
Waarom worden te vroeg geboren kinderen oogheelkundig onderzocht?
Bij een klein aantal kinderen met ROP ontstaat een ernstige vorm die behandeld moet 
worden. Met deze behandeling wordt geprobeerd om blind- of slechtziendheid te voor-
komen. Om die behandeling tijdig te kunnen uitvoeren is het belangrijk dat ROP in een 
vroeg stadium herkend wordt. Dit gebeurt door middel van een oogonderzoek.
Welke kinderen worden gescreend?
Kinderen die bij hun geboorte minder dan 1250 gram wegen en/of geboren zijn na een 
zwangerschapsduur die korter is dan 30 weken
en
Kinderen die bij hun geboorte tussen de 1250 gram en 1500 gram wegen en/of gebo-
ren zijn na een zwangerschapsduur tussen de 30 en 32 weken, die één van de volgende 
behandelingen / aandoeningen hebben gehad: beademing, sepsis, necrotiserende 
enterocolitis (NEC), behandeling met bepaalde medicijnen (cardiotonica) vanwege lage 
bloeddruk of behandeling met corticosteroïden na de geboorte. 
ROP screening
U krijgt deze folder omdat uw kind gescreend 
moet worden op een oogaandoening: 
prematurenretinopathie. Hierin kunt u 
nog eens nalezen waarom dit onderzoek 
noodzakelijk is bij uw kind.
Deze folder is tot stand gekomen in samenwerking met:
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Zones
De mate van uitgroei van de bloedvaten wordt ingedeeld in 3 zones. In zone 1 zijn de 
bloedvaten het minst uitgegroeid en in zone 3 vrijwel volledig.
Stadia
ROP kent 5 stadia waarvan stadium 1 en 2 het meeste voorkomen. Dit zijn de mildste 
vormen. 
Bij stadium 3 ontstaan er woekeringen van de bloedvaten en neemt de kans op bloedin-
gen uit deze slechte bloedvaten toe.
Door bloedvaten die het oog in groeien en bloedingen in het oog, kan het netvlies van 
zijn plaats getrokken worden. In stadium 4 heeft het netvlies gedeeltelijk en in stadium 5 
helemaal los gelaten. Dit laatste wordt ook wel het eindstadium van ROP genoemd.
Plus disease
Er wordt ook naar de dikte en kronkeling van de bloedvaten gekeken. Als de vaten 
erg dik en kronkelig zijn wordt dit ‘plus disease’ genoemd. Het aanwezig zijn van plus 
disease is geen goed teken, en meestal een reden om te behandelen. 
Foto van niet volledig uitgegroeide 
bloedvaten.
De pijltjes wijzen naar de plaats 
waar de uitgroei 
van bloedvaten gestopt is.
Foto van ROP. 
De pijltjes wijzen naar de overgang 
van het gebied met en zonder 
bloedvaten. 
Op de overgang is een verdikte wal 
te zien met vaatwoekeringen .
Ook zijn de vaten op deze foto 
dikker, dit is een teken van ‘plus 
disease’.
Er is hier sprake van een ROP 
stadium 3+
Sommige ziekenhuizen onderzoeken alle kinderen met een geboortegewicht onder de 
1500 gram en/of een zwangerschapsduur korter dan 32 weken.
Uw arts kan u hier meer over vertellen.
Wanneer wordt gescreend?
Het eerste onderzoek vindt in de 5e week na de geboorte plaats, maar niet voor de 31e 
week van de oorspronkelijke zwangerschapsduur.
Afhankelijk van de resultaten van het onderzoek en de leeftijd van uw kindje kan het 
nodig zijn dat het onderzoek na een aantal weken herhaald wordt.
Hoe verloopt het onderzoek?
Het opsporen van ROP gebeurt in de meeste gevallen door middel van een ’oogspiegel 
onderzoek’. In sommige ziekenhuizen maakt men gebruik van een speciale fotocamera, 
de Retcam.
Uw kindje krijgt eerst meerdere oogdruppels toegediend door de verpleging. Deze oog-
druppels zorgen ervoor dat de pupillen wijd worden. Dit is noodzakelijk om het netvlies 
goed te kunnen beoordelen.
Nadat de druppels goed zijn ingewerkt kijkt de oogarts. De verpleegkundige assisteert 
tijdens het onderzoek en zorgt voor een comfortabele en goede positie van de baby.
Soms vindt het onderzoek niet plaats op de afdeling waar uw kindje opgenomen is maar 
bijvoorbeeld op de polikliniek oogheelkunde.
Om het oog goed open te houden tijdens het onderzoek, wordt een spreidertje tussen de 
oogleden geplaatst. Dit vinden ouders vaak vervelend om te zien. Om te voorkomen dat 
uw kindje last heeft van het spreidertje geeft de oogarts vooraf verdovende oogdruppels. 
De oogarts onderzoekt vervolgens het oog op tekenen van ROP. Hiervoor schijnt hij met 
een lampje in het oog, en kijkt door een loep naar het netvlies. Het onderzoek zal onge-
veer een kwartier in beslag nemen. Tijdens het onderzoek huilen kindjes soms omdat zij 
het felle licht niet prettig vinden.
 
Ontstaan en indeling van ROP
Wanneer de bloedvaten die het netvlies van voeding voorzien niet voldoende uitgegroeid 
zijn, kan zuurstoftekort ontstaan in dat deel van het netvlies waar nog geen bloedvaten 
gegroeid zijn. Het netvlies probeert dit zuurstoftekort te corrigeren en gaat stofjes (an-
giogene factoren) afgeven die de uitgroei van bloedvaten stimuleren. Wanneer te veel 
van deze stofjes worden afgegeven kunnen woekeringen van de bloedvaten ontstaan. 
Omdat deze bloedvaten van slechte kwaliteit zijn kunnen ze gaan lekken en daardoor 
kan in het ergste geval het netvlies loslaten.
ROP wordt ingedeeld in zones en stadia.
ROP information folder 157
AZones
De mate van uitgroei van de bloedvaten wordt ingedeeld in 3 zones. In zone 1 zijn de 
bloedvaten het minst uitgegroeid en in zone 3 vrijwel volledig.
Stadia
ROP kent 5 stadia waarvan stadium 1 en 2 het meeste voorkomen. Dit zijn de mildste 
vormen. 
Bij stadium 3 ontstaan er woekeringen van de bloedvaten en neemt de kans op bloedin-
gen uit deze slechte bloedvaten toe.
Door bloedvaten die het oog in groeien en bloedingen in het oog, kan het netvlies van 
zijn plaats getrokken worden. In stadium 4 heeft het netvlies gedeeltelijk en in stadium 5 
helemaal los gelaten. Dit laatste wordt ook wel het eindstadium van ROP genoemd.
Plus disease
Er wordt ook naar de dikte en kronkeling van de bloedvaten gekeken. Als de vaten 
erg dik en kronkelig zijn wordt dit ‘plus disease’ genoemd. Het aanwezig zijn van plus 
disease is geen goed teken, en meestal een reden om te behandelen. 
Foto van niet volledig uitgegroeide 
bloedvaten.
De pijltjes wijzen naar de plaats 
waar de uitgroei 
van bloedvaten gestopt is.
Foto van ROP. 
De pijltjes wijzen naar de overgang 
van het gebied met en zonder 
bloedvaten. 
Op de overgang is een verdikte wal 
te zien met vaatwoekeringen .
Ook zijn de vaten op deze foto 
dikker, dit is een teken van ‘plus 
disease’.
Er is hier sprake van een ROP 
stadium 3+
Sommige ziekenhuizen onderzoeken alle kinderen met een geboortegewicht onder de 
1500 gram en/of een zwangerschapsduur korter dan 32 weken.
Uw arts kan u hier meer over vertellen.
Wanneer wordt gescreend?
Het eerste onderzoek vindt in de 5e week na de geboorte plaats, maar niet voor de 31e 
week van de oorspronkelijke zwangerschapsduur.
Afhankelijk van de resultaten van het onderzoek en de leeftijd van uw kindje kan het 
nodig zijn dat het onderzoek na een aantal weken herhaald wordt.
Hoe verloopt het onderzoek?
Het opsporen van ROP gebeurt in de meeste gevallen door middel van een ’oogspiegel 
onderzoek’. In sommige ziekenhuizen maakt men gebruik van een speciale fotocamera, 
de Retcam.
Uw kindje krijgt eerst meerdere oogdruppels toegediend door de verpleging. Deze oog-
druppels zorgen ervoor dat de pupillen wijd worden. Dit is noodzakelijk om het netvlies 
goed te kunnen beoordelen.
Nadat de druppels goed zijn ingewerkt kijkt de oogarts. De verpleegkundige assisteert 
tijdens het onderzoek en zorgt voor een comfortabele en goede positie van de baby.
Soms vindt het onderzoek niet plaats op de afdeling waar uw kindje opgenomen is maar 
bijvoorbeeld op de polikliniek oogheelkunde.
Om het oog goed open te houden tijdens het onderzoek, wordt een spreidertje tussen de 
oogleden geplaatst. Dit vinden ouders vaak vervelend om te zien. Om te voorkomen dat 
uw kindje last heeft van het spreidertje geeft de oogarts vooraf verdovende oogdruppels. 
De oogarts onderzoekt vervolgens het oog op tekenen van ROP. Hiervoor schijnt hij met 
een lampje in het oog, en kijkt door een loep naar het netvlies. Het onderzoek zal onge-
veer een kwartier in beslag nemen. Tijdens het onderzoek huilen kindjes soms omdat zij 
het felle licht niet prettig vinden.
 
Ontstaan en indeling van ROP
Wanneer de bloedvaten die het netvlies van voeding voorzien niet voldoende uitgegroeid 
zijn, kan zuurstoftekort ontstaan in dat deel van het netvlies waar nog geen bloedvaten 
gegroeid zijn. Het netvlies probeert dit zuurstoftekort te corrigeren en gaat stofjes (an-
giogene factoren) afgeven die de uitgroei van bloedvaten stimuleren. Wanneer te veel 
van deze stofjes worden afgegeven kunnen woekeringen van de bloedvaten ontstaan. 
Omdat deze bloedvaten van slechte kwaliteit zijn kunnen ze gaan lekken en daardoor 
kan in het ergste geval het netvlies loslaten.
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Kalenderweek 1ste screening: 
ROP onderzoeksformulier 
Gegevens patiënt / patiëntensticker    Zwangerschapsduur: 
        Geboortegewicht: 
Naam:       Beademing   ja / nee 
BSN:        Postnatale steroïden ja / nee  
Geboortedatum:      Sepsis     ja / nee 
        NEC      ja / nee 
        Cardiotonica    ja / nee 
      
